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ABSTRACT
Asthma-COPD Overlap: Economic Burden and Medication Adherence
Mona Nili

In many older adults, asthma and chronic obstructive pulmonary disease (COPD) coexist as
“Asthma-COPD overlap” (ACO). This dissertation pursued three Aims: 1) estimate the
economic burden of ACO and its contributory factors; 2) evaluate the association of ACO to
“cost-related medication nonadherence” (CRN); and 3) identify adherence trajectory patterns and
examine the impact of initial maintenance therapies (IMT) type (inhaled corticosteroids
monotherapy (ICS) vs. fixed-dose combination of ICS and long-acting beta agonist
(ICS/LABA)) on adherence trajectory patterns among older adults Medicare Beneficiaries. The
first and second Aims were cross-sectional studies by using Medicare Current Beneficiary
Survey data. For the third Aim, we used a longitudinal retrospective cohort design, using 10%
sample of Optum’s Deidentified Clinformatics®. In this study, older adults with ACO had nearly
four times higher average total healthcare expenditures compared to those no-asthma no-COPD
(NANC). The higher number of medications and fragmented care were the leading contributors
of the economic burden. Moreover, compared to older adults with NANC, those with ACO were
more likely to report any CRN. This association was highly dependent on number of
medications. In addition, we identified four medication adherence trajectories to IMT among
older adults with ACO. Those who using ICS/LABA were less likely to have “persistent low
adherence” (Adjusted Odds Ratio= 0.38). In summary, these findings highlight the need to
reduce the economic burden and improve medication adherence among older adults with ACO.
Additionally, using ICS/LABA for IMT may improve adherence to IMT among older adults with
ACO.
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CHAPTER 1
1 Introduction
1.1 Background and Significance
Epidemiology of Major Depressive Disorder
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are the two most common
respiratory diseases in the world. Combined, more than 435 million adults suffer from asthma or
COPD. 1,2. The economic burden of asthma ($82 billion in 20153) and COPD ($49 billion
projected in 20204) in the United States are very high. Clinicians can easily make these
distinctions. Asthma usually develops in childhood, has classic symptoms of chest tightness,
wheezing, coughing, and dyspnea, and is more likely to be associated with atopic disorders.
COPD usually manifests later in life with dyspnea and productive cough and more likely be
associated with environmental factors such as tobacco smoking.
Definition of Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)
In 2009, Gibson and Simpson reported that about half of the older patients with obstructive
airway disease have overlapping symptoms of both asthma and COPD. They called this the
asthma-COPD “overlap syndrome”5. In 2013, “asthma-COPD overlap syndrome” (AOCS) was
used to describe this condition which is still used in many studies6. However, recent studies have
suggested that it is better to describe this condition as “asthma COPD overlap” (ACO) without
using “syndrome” since there is no specific definition of syndrome for this condition7. Thus, in
our study, we use the term ACO when asthma and COPD co-exist in the same individual.
Prevalence of ACO
In the general population, the estimated prevalence of ACO varies widely across studies
based on the definitional criteria of ACO and time period. Using the National Health and

1

Nutrition Examination Survey (NHANES)-III (1988–1994) data, Diaz-Guzman et al. estimated
that the prevalence of ACO was 2.7%8. However, and estimated the prevalence of ACO was
estimated at 0.96% in the period spanning 2007–2012. Prevalence of ACO among individuals
with COPD or Asthma.
The prevalence of ACO among patients with either asthma or COPD is higher than the
general population. According to the findings of a meta-analysis, the global prevalence of ACO
among patients with asthma is 26.5% and among patients with COPD is 29.6%9 However, the
prevalence of ACO can be as high as An estimated 50% patients with asthma or COPD9. Among
patients with obstructive lung diseases, the prevalence of ACO is less than 10% among younger
patients (< 50 years) and more than 50 % among older patients (>80 years or older)10. Similar
results on age distribution were found in the Italian population6.
Disease Burden of ACO
Disease burden of a condition is often measured with morbidity, health-related quality of
life, mortality, healthcare utilization and costs. ACO patients experience substantial disease
burden. In terms of mortality, ACO may be associated with a higher mortality compared with
either asthma or COPD. In the NHANES-III cohort, Diaz-Guzman et al found that the hazard
ratio (HR) for mortality in ACO is the highest (1.8), compared with COPD (1.4) and asthma
(1.2)8. These findings contrast with few other studies where ACO have not increased risk of
negative consequences. For example, a study of older adults (>55 years old) with progressive
obstructive airway disease found that COPD patients had a worse prognosis compared to patients
with ACO11. Bai et al also found that patients with ACO had higher likelihood of better
prognoses and lower mortality compared to patients with COPD alone, though with a heightened
exacerbation frequency.
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In a cohort of 17,088 COPD patients in Taiwan, ACO patients experienced almost twice
as many acute respiratory events (i.e. acute respiratory failure, pneumonia, acute exacerbation,
and cardiopulmonary arrest) than did the rest of the COPD cohort12. In the Latin American
Project for the Investigation of Obstructive Lung Disease (PLATINO), patients with ACO had
worse lung function, had more respiratory medications, experienced more exacerbations and
hospitalizations and reported a worse perception of general health status than patients with only
either asthma or COPD13.
The prevalence of co-existing health conditions is also higher in ACO compared to either
asthma or COPD. A population survey in the US found that patients with ACO found that 90%
of respondents had at least one other co-existing condition (compared with 71% in asthma and
84% in COPD)14. When analyzed by type of eight chronic comorbid conditions (e.g.
cardiovascular diseases, diabetes, and depression), the prevalence of all eight conditions were
higher in ACO compared to asthma, and six out of eight conditions were more prevalent in ACO
compared to COPD.
Economic burden of ACO
The high morbidity burden experienced by patients with ACO may also translate into high
healthcare utilization and high healthcare costs. Using the 2009 Korean National Health
Insurance database on 185,147 COPD patients, Rhee et al found that those with ACO had a
higher frequency of emergency department visits, hospitalization and intensive care unit visits
than patients with only COPD15. In this study, healthcare utilization and costs were significantly
higher for both outpatient and inpatient care for ACO patients compared to those with only
COPD or only asthma15. In a retrospective cohort study in Taiwan, patients with ACO had the
higher medication costs, and experienced more respiratory-related hospital visits compared to
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patients with asthma or COPD16. In Canada, a retrospective cohort study reported that costs of
medications and outpatient services were higher in ACO patients, but costs of hospitalizations
were lower compared to patients with COPD. In this study, costs of non-respiratory conditions
were lower in ACO, mainly due to lower costs of cardiovascular diseases.
Most of the studies on economic burden of ACO has been conducted mainly outside the
United States (US). There have been only two studies in the US on the economic burden of
ACO. A retrospective cohort analysis of commercial claims in the US, both asthma-related and
all-cause health care expenditures were twice as high for patients with ACO compared to those
with only asthma17. Among enrollees of Medicare Advantage Plan in 2004, Blanchett et al found
that mean unadjusted respiratory-related health care expenditures were $7,240 for the patients
with ACO and $5,158 for patients with COPD18. However, these studies were conducted a
decade ago and the estimates are dated. Furthermore, the contributing factors to the excess cost
of ACO remains unknown. The presence of comorbidities, more frequent exacerbations, and
higher healthcare and medication utilization may be the major drivers of this excess cost.
The Importance of Medication Use in ACO
An important goal of ACO management is slowing the progression of the disease as there
is no cure for ACO. Inhaler medications play an important role slowing the progression of the
disease. For example, medication fluticasone furoate/vilanterole, as an ICS/LABA, has been
shown to substantial improvement in lung functions19. Therefore, adherence to medication is
expected to be important among individuals with ACO. Although very limited evidence support
the effect of adherence to inhaler medication and clinical outcomes, previous studies among
patients with COPD and asthma support this20,21.
Link between Medication Nonadherencee and Economic Burden
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Medication non-adherence is generally a source of considerable cost to the U.S. health
care system22. Because medication adherence can accelerate the progression of the disease
leading to hospitalizations, emergency room visits and other healthcare services. Osterberg and
Blaschke estimated that medication non-adherence contributes to approximately $100 billion in
hospitalizations and $2,000 per patient annually in excess physician visits.23 Among Medicare
beneficiaries with COPD, Simoni-Wastila et al estimated that patients who were not adherent to
their medications had $2,185 higher costs compared with patients who adhered to their
medication24. Specific to asthma and COPD, medication adherence to maintenance therapy is
critical to slow the progression of disease. For example, a retrospective cohort study reported that
poor adherence to initial maintenance therapy was associated with progression of disease among
patients with moderate to severe asthma25.
Medication Nonadherencee among Adults with ACO
As there are no published studies on medication adherence among ACO patients, we
speculate that ACO patients may be particularly vulnerable to medication non-adherence based
on published literature focusing on either asthma or COPD or chronic respiratory conditions. As
asthma and COPD are chronic conditions, patients with ACO are expected to use medications for
asthma as well as COPD for the remainder of their lives. In general, medication adherence
among patients with chronic pulmonary disease is lower compared to other chronic conditions,
including rheumatologic conditions, HIV, cancer, and gastrointestinal disorders 26 In a systematic
review with more than 2,000 subjects with asthma using ICS, medication adherence ranged from
47% to 57%27. Similarly, a study of 244 patients with COPD reported that adherence to
ICS/LABA was less than 23%28. Non-adherence with long-acting bronchodilators was found
among 65% of 45,000 patients with COPD in Germany29. This number was 70% among 11,000
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COPD patients in the US Veterans Affairs database30. Poor adherence to maintenance therapy is
particularly higher among the elderly population. In a retrospective cohort study on Medicare
beneficiaries with COPD, the average monthly adherence to IMT was very low 31. In this study,
the highest medication adherence was in the second month (0.57) and decreased rapidly before
plateauing at 0.35 by the seventh month31.
Higher Vulnerability of Older Adults with ACO to Medication Non-Adherence
Older adults with ACO may be at higher risk for medication non-adherence due to high
medications costs32. Specifically, adherence to maintenance therapy may also be lower due to
therapy-related factors such as medication type, ease of administration, ease of dosing33. While
high cost of medications and medication-related factors can affect adherence among all patients
with ACO, the older patients may be at a higher risk due to a unique set of circumstance (such as
the high prevalence of comorbid conditions, low socio-economic status, and high rates of
polypharmacy).
Cost Related Medication Non-Adherence (CRN) among Older Adults with ACO
The primary socioeconomic factors influencing medication non-adherence are access to
prescription benefits and out-of-pocket expenses34. Without appropriate drug coverage,
maintenance medications are cost prohibitive as generic maintenance medications have not been
available in the United States35. In the US, most older patients are covered by Medicare
insurance36. Although since 2006 Medicare Part D provided prescription drug coverage to
increase access to prescription medications for the elderly population, most Medicare plans have
drug coverage gaps (e.g. donut hole) that can create financial distress for the elderly patients37.
High out-of-pocket contributions can increase CRN among elderly Medicare beneficiaries38.
Moreover, formulary tiers make some of the most effective maintenance medications
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inaccessible35. Affected older patients often respond to the drug coverage gap by using costcoping behaviors (e.g. forgoing mortgage payments) and CRN behaviors (e.g. skipping some
doses of medication for stretching medication possession time)39. Medicare beneficiaries with
chronic health conditions have a higher risk of CRN behaviors.40–42 In 2006 Castaldi et al
estimated that the prevalence of CRN is 31% among Medicare beneficiaries with chronic
pulmonary diseases (e.g. asthma or COPD).32 They did not specify which chronic pulmonary
diseases increases the risk of CRN. By considering the negative health outcomes of ACO, we
patients with ACO may be at high risk of CRN.
Treatment-Related Factors and Medication Non-Adherence
Type and complexity of treatment are some of the many medication-related factors that
may affect adherence to maintenance therapy among patients with asthma and COPD
medications35. Most of the elderly patients are required to take multiple medications each day;
many of these medications need more than one daily dose. ACO patients, who are already on
complex regimens, adhering to complex regimen maintenance medications is challenging43 and
consequently may lead to medication non-adherence. Furthermore, maintenance medications use
inhalers and older patients may face challenges in self-administering inhaler medications.
Misperceptions about maintenance medications may also lead to medication nonadherence older
patients44. For instance, fast relief by using short-acting bronchodilator can be perceived as a
measure of potency. This can result in mistakenly prioritized short acting bronchodilators over
maintenance medicines (e.g. ICS). Fears of addiction to ICS or developing a tolerance is also
very common which can lead to poor adherence to maintenance medications 45.
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Possible Impact of Medication Type on Medication Non-Adherence
The joint guidelines of GINA and GOLD for treating ACO recommend ICS for IMT. The
other IMT option for patients with ACO is ICS/LABA. The earliest use of ICS/LABA for IMT
in treatment for ACO patients is supported by a study conducted by Gershon and colleagues 46. In
a case-control study, they demonstrated that newly prescribed ICS/LABA therapy, compared
with LABA alone, was associated with a significantly lower risk of COPD hospitalization or
death among ACO patients. Moreover, in a 12-week randomized open-label cross-over study,
ACO patients experienced significant improvement in vital capacity after eight weeks ICSLABA treatment19. Prescribing ICS/LABA as IMT for ACO has two main advantages. First,
ACO has both inflammatory and obstructive nature. Therefore, adding LABA to ICS can reduce
obstruction. Second, using LABA is associated with a decreased risk of myocardial infarction,
hospitalization, and death among patients with ACO47.
Although both ICS and ICS/LABA are possible options for IMT of ACO, their impact on
adherence is unknown. A study of asthma patients reported poor medication adherence to IMT
when ICS is in fixed-dose combination with LABA (ICS/LABA) compared to ICS
monotherapy48. As medication adherence in general declines over time for respiratory and other
conditions, there is a need to examine trajectories of medication adherence among ACO patients
by types of IMT.
In summary, scientific studies of contributory factors to economic burden, cost-related
mediation non-adherence and the impact of the type of maintenance therapy on adherence over
time among ACO patients is non-existent. A deeper understanding of these issues is critical to
providers as well as policy makers including CMS, patients, and providers. Contributory factors
of the economic burden can be used by CMS in deriving risk-based cost estimates that are being
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used in value-based reimbursement models. The possible association of ACO to CRN for
developing targeted intervention to reduce CRN. Our cost estimates can also be used to evaluate
cost-effectiveness of interventions of care for ACO patients. By examining the possible impact
of medication type (ICS/LABA vs ICS) on medication adherence, our study findings can provide
real-world evidence on adherence patterns.
1.2 Innovation
a) The present study will be a “series of firsts.” The study findings will fill a knowledge gap
in the health outcomes of ACO in a nationally representative sample of the community
dwelling Medicare beneficiaries in the US. For example, this is the first study to evaluate
contributing factors to cost burden, CRN and long-term Medicare adherence among ACO
patients.
b) Leveraging data from nationally representative surveys and medical claims data, we are
able to have the “best of both worlds”. The unique feature of MCBS-linked Medicare is
the linkage between survey data and Medicare claims. In the survey component of the
MCBS, the self-reported information not available in insurance claims databases (e.g.
functional limitations, health status, smoking habit, and others). The Medicare claims
component provides fee-for-service claims for both Part A and B. These claims include
information on treatment, diagnosis, health services utilization, and Medicare payments 49.
c) Generate new knowledge that may be used to improve medication adherence by
evaluating modifiable factors such as regimen complexity and the out-of-pocket cost
burden on CRN.
d) The application of advanced econometric and novel methods such as “group-based
trajectory modeling” (GBTM). GBTM has been extensively applied in psychology, and

9

criminology, but very few studies evaluated medication adherence using GBTM.
Longitudinal evaluation of adherence using GBTM can yield more useful classifications
compared to traditional methods such as proportion of days of coverage (PDC).
1.3 Specific Aims
AIM 1: Estimate the excess economic burden of ACO (direct healthcare expenditures) and
its contributory factors among older Medicare beneficiaries using post-regression
decomposition techniques.
Hypothesis: A majority of the excess economic burden of ACO can be explained by
medication non-adherence, fragmented care, and the presence of other comorbidities.
AIM 2: Evaluate the adjusted association of ACO to CRN among older Medicare
beneficiaries.
Hypothesis: Older adults with ACO will be more likely to report CRN and this can be
explained by medication regimen complexity and a high out-of-pocket (OOP) cost
burden.
AIM 3: Examine the impact of medication type (ICS vs ICS/LABA) on adherence over time
among ACO patients who initiated maintenance therapy.
Hypothesis: Adults with ACO who use ICS/LABA have poorer adherence to maintenance
therapy over time.
1.4 Approach
Conceptual Framework
We adopted features from the Anderson Health behavior model50 to study all aims in this
study (Figure 1). This model has been used in many studies with different health conditions to
study health care expenditures. According to this model, health care expenditure is determined
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by five factors: (1) predisposing factors, (2) enabling factors, (3) need factors, (4) personal health
practices, (5) external factors. Predisposing factors are those reflecting an individual’s propensity
to use health services. These include factors like age, race/ethnicity, etc. Enabling factors are
those that facilitate access to health care services. Examples of enabling factors include
education status, health insurance coverage. etc. Need factors are potential needs for health
services use, for example presence of comorbidities. Personal health practices factors reflect an
individual’s lifestyle. These include factors such as smoking habits and obesity. External factors
are those related to environmental factors (e.g. region of residency).
Figure 1.1
Conceptual Framework for Factors Associated with Healthcare Expenditures
Adapted from Anderson’s Model

Data Sources
We will leverage multiple data sources to accomplish our research Aims. For Aims 1 and 2,
we will use Medicare Current Beneficiary Survey (MCBS) linked to Medicare claims. For Aim
3, we will use the 10% random sample of Optum Clinformatics Data Mart®.
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MCBS
The MCBS is a continuous, multipurpose survey of a nationally representative sample of the
Medicare population, conducted by CMS. The MCBS is conducted on a representative sample of
Medicare beneficiaries. The survey is repeated annually for three years 51. All participants are
interviewed in person or with computer-assisted personal interview technology. From 1991 to
2013, the MCBS released two data files, the Access to Care (AC) and the Cost and Use (CU)
annually, although the samples in both files share substantial overlap. The AC file can be linked
to the CU file. Each year of the MCBS may be used for cross-sectional analyses or for
conducting longitudinal analyses. We will use following files for Aims 1 and 2:
MCBS - Access to Care (AC) Files: The AC files contain information on beneficiaries’ sociodemographics, self-reported health status and conditions, health insurance coverage, medication
adherence, and cost-related medication adherence. The AC files represent the “always enrolled,”
Medicare beneficiaries. This file does not include survey-reported use of health care services and
costs.
MCBS – Cost and Use (CU) Files: The CU file is designed to provide a complete user file,
and it uses an “ever enrolled” population. The “ever enrolled” population includes health care
services and costs for all Medicare beneficiaries who joined the program during the year and
those who died during the year. The CU file includes survey reports for services not included in
Medicare billing files (e.g. prescription drugs). Moreover, for Medicare covered services, the
accuracy of service types, payments, and sources of payment has been improved by using an
extensive operation to match and reconcile survey reports and Medicare bills.
MCBS – Medicare Claims Files: The CU and AC files can be linked to Medicare Fee-forService claims data. This will provide a unique opportunity for researchers to obtain a
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comprehensive picture of health services received, sources of payment, amounts paid, and
including payments which are not covered by Medicare49. Medicare claims files include all Part
A and B claims files. However, there is no separate file for Part D events. Information about
prescription medications are is available in Prescribed Medicine Event (PME) file within the CU
file.
10% Random Sample of Optum Clinformatics Data Mart®
This database provides a nationally representative source of data on inpatient, outpatient and
pharmacy claims, lab results, and some demographic characteristics. This dataset is a 10%
random sample of health insurance claims from approximately 47 million individuals, 80% of
whom were insured through their employment52. Data are available for periods between January
2007 and October 2017. We will use available data from October 2007 to October 2017.
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CHAPTER 2
2 Economic Burden of Asthma- Chronic Obstructive Pulmonary Disease Overlap (ACO)
among Older Adults in the United States
2.1 Abstract
The objectives of this study are to estimate the excess economic burden of AsthmaChronic Obstructive Pulmonary Disease Overlap (ACO) among older adults in the United States
and to evaluate the extent to which group differences in patient-level characteristics contribute to
this excess economic burden. We used a cross-sectional study design with data from a nationally
representative survey of Medicare beneficiaries (Medicare Current Beneficiary Survey) linked to
Medicare fee-for-service claims. Economic burden was measured by total, third-party healthcare
expenditures and patients’ out-of-pocket spending (i.e. spending more than 10% of income on
healthcare). Generalized Linear Models (GLM) and post-regression linear and non-linear
decomposition methods were used to analyze the excess economic burden of ACO. Older adults
with ACO had unfavorable profiles including a higher number of prescription medications
utilized (mean 16.12+7.27 vs. 7.53+5.32) and increased levels of fragmented care (78.08+12.01
vs. 66.80+22.17). Older adults with ACO had higher average total healthcare expenditures
($45,532 vs. $12,743) and higher out-of-pocket spending burden (19% vs. 8.5%) compared to
those without asthma or COPD. Multivariable regression models indicated that the adjusted
associations of ACO to economic burden remained positive and statistically significant. Nearly
three-quarters of the excess total healthcare expenditures and 83% of the out-of-pocket spending
burden were explained by differences in predisposing, enabling, need, personal healthcare
practices, and external factors among the two groups. The higher number of unique medications
and the increased incidence of fragmented care were the leading contributors of the excess
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economic burden among older adults with ACO. Interventions that reduce number of
medications and fragmented care have the potential to reduce the excess economic burden
among older adults with ACO.
2.2 Introduction
In the United States (US), chronic obstructive respiratory disease in older individuals occurs
most often as COPD or asthma53. Among 15–45% of older adults initially diagnosed with COPD
or asthma, can later develop “Asthma-COPD overlap” (ACO) with symptoms consistent with
each disease state 9. A significant disease burden and adverse health consequences exist for ACO
patients compared to patients with either asthma only or COPD only. Prior research suggest that
ACO patients experience higher acute respiratory events, outpatient visits, and hospitalizations
compared to those with either asthma only or COPD only12,13,53. The prevalence rates of
comorbid medical conditions and polypharmacy are also higher in ACO compared to either
asthma or COPD14, suggesting that adults with ACO may constitute a significant economic
burden.
However, current estimates of the economic burden of ACO in older adults are unknown.
There have been only two studies in the US on the economic burden of ACO. The first study was
conducted among enrollees of Medicare Advantage Plan in 2004. This study found that the
average annual healthcare expenditures for the patients with ACO is higher than patients with
COPD only18. The second study was a retrospective commercial claims analysis which reported
that healthcare expenditures were twice as high for patients with ACO compared to those with
asthma only between 2007-201017. Neither of these studies provided any information on average
total healthcare expenditures, out-of-pocket (OOP) expenditures, and high OOP spending burden
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of older adults with ACO or compared economic burden with those who had no-asthma noCOPD (NANC).
Estimating the excess economic burden of ACO is important for several reasons. First,
there is an emerging focus on achieving optimal healthcare with the triple aims of better health,
higher quality, and lower costs54. For reducing overall healthcare costs, identification and
management of high-cost conditions are very important55. Second, reducing costs also requires
innovative practice models and payment reforms 56. For example, innovative payment models
such as bundled payments for episodes of care need critical information on high-cost individuals
as part of case mix adjustments 57. Third, estimating the excess economic burden can provide
benchmarks for deriving cost-effectiveness of targeted interventions for management of ACO 58.
Finally, estimating the economic burden of ACO can translate disease burden into a universal
metric (i.e. monetary value) which can be used for decision making by payers, policymakers, and
other stakeholders 59.
In addition to excess economic burden, it is important to assess the high OOP spending
burden because this can lead to poorer health-related behavior (e.g. poor medication
adherence)60, poorer health outcomes, and increased future expenses61. High OOP spending
burden is quite common among the older adults in the US. Although many older adults have
health insurance coverage through Medicare, not all services are fully covered. This leaves many
individuals paying for their healthcare through OOP payments. A study of older adults conducted
by West Health and Gallup reported that the older adult population spent nearly $22 billion from
their savings to pay for healthcare, suggesting that older individuals may not have the financial
resources to manage their health when they need it the most62. It has to be noted that nearly a
quarter of Medicare beneficiaries have less than $15,000 in total savings63. Although we do not
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have estimates of OOP payments among ACO patients, existing literature on OOP spending
burden of either COPD or asthma suggest that OOP spending can be substantial. For example,
the annual OOP costs of a single COPD inhaler per month was estimated to be about $900 under
a standard 2015 Part D plan64.
Although quantifying excess economic burden of ACO can provide needed information
for decision making, it may not provide enough information to act on because costs are
influenced by many factors including severity, care fragmentation65, age66, and presence of other
chronic conditions.67 Similarly, high OOP spending burden is affected by many patient-level
characteristics (e.g. age68, comorbidities69, income level70). Understanding the extent to which
differences in patient-level factors drive the excess economic burden and high OOP spending
burden of ACO is vital to case-mix adjustment, allocation of resources, payment reforms, costsharing, and cost reduction efforts.
Therefore, the main objectives of this study are to quantify the economic burden of ACO
using data from a nationally representative sample of Medicare beneficiaries, and estimate the
extent to which differences in characteristics among patients with ACO and NANC explained
this economic burden.
2.3 Methods
Study Design
This study used a cross-sectional study design by using data from multiple years of linked
fee-for-service Medicare claims with a nationally representative survey of Medicare
beneficiaries.
Data Source
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This study used the Medicare Current Beneficiary Survey (MCBS) linked to fee-for-service
Medicare claims from 2006 through 2013. The MCBS is a rotating four-year panel survey of a
nationally representative sample of individuals enrolled in Medicare Part A and B. The survey
data sources provide information on direct medical costs, sources of payment, OOP payments, ,
health outcomes, clinical diseases, and sociodemographic of beneficiaries 51. To improve the
completeness and accuracy of medical costs and utilization, survey data are matched with feefor-service Medicare claims for making best of both claims and survey data worlds 49. For this
study, we used Medicare claims files for capturing information on health conditions and thirdparty payments. We also used “Cost and Use” (CU) survey files for deriving OOP burden and
other variables (e.g. sex, age, race, prescription coverage, education level, disability status,
smoking habit, and residency region).
Study Sample
The final analytical sample consisted of 38,089 person years and included communitydwelling Medicare beneficiaries, 65 years or older, alive throughout the calendar year, and
enrolled in both Parts A and B fee-for-service during the calendar year. (Appendix 7.1)
Measures
Dependent Variables: Economic Burden
Total HealthCare Expenditures
All expenditures information in MCBS linked to Medicare claims files was extracted
through a reconciliation process by combing survey information and Medicare claims files 51.
Linking these files provide a unique opportunity of cost analyses on the Medicare population
compared to using either survey data or claims data alone49. Respondents to survey utilized
calendars to record their medical events and were asked to save all their receipts from insurance
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companies, their receipts, and prescription bags provided by the pharmacy. Total healthcare
expenditures were calculated by adding all the expenditures for inpatient visits, outpatient visits,
prescription drugs, medical provider services, dental services, and other medical services.
Sources of payment included both third-party expenditures and out-of-pocket (OOP)
expenditures.
Third-party Expenditures
The third-party payers in this study included Medicare, Medicaid, private insurances,
Veterans Affairs Health insurance, and other payers. We calculated third-party expenditures by
subtracting OOP payments from total healthcare expenditures. To account for inflation of
medical services, all the expenditures were converted to 2013-equivalent US dollars, by using
the annual consumer price index of medical services 71.
High OOP Spending Burden of Individuals and Families
OOP expenditures in the MCBS represented amount spent by the patients or their
families on healthcare, but not include insurance premium. To capture OOP expenditures,
respondents of the MCBS were asked to record all the details of what they spent on healthcare
bills and what they expected to spend on additional bills51. Respondents also reported their
household income. OOP spending burden” was calculated as the ratio of OOP to income. Older
adults who spent more than 10% of their income on healthcare, were classified as having high
OOP burden.
Spending more than 10% of income on healthcare may compromise essential living
expenses such as housing and food. As there is no consensus on the definition of OOP burden,
we chose the 10% threshold based on previously published literature which reported that this
threshold is above generally accepted affordability standards 61,72.
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Key Independent Variable: Asthma/ COPD categories
The key independent variable of this study was asthma/COPD categories. Individuals
with either asthma or COPD were identified by using the International Classification of Diseases,
9th edition diagnostic codes available in fee-for-service Medicare claims (Appendix 7.2). We
used inpatient, outpatient, physician, skilled nursing home, and home healthcare claims. The
diagnosis codes for identification of asthma and COPD cases have been used in previously welldesigned published research73,74. Individuals with a minimum of two outpatient visits (14 days
apart) or one inpatient visit for asthma were considered to have asthma. Older adults with one
inpatient or two outpatient visits (14 days apart) for COPD were categorized as individuals with
COPD. Based on the presence of asthma or COPD, we created the following four asthma/COPD
categories: 1) Asthma COPD Overlap (ACO); 2) Asthma only; 3) COPD only; and 4) No
Asthma no COPD (NANC).
Other independent variables
The selection of other independent variables that could affect expenditures were derived
from published literature 75,76 and guided by Andersen’s Healthcare Behavioral Framework 50.
Based on the model, the healthcare outcomes (in our study total healthcare expenditures) is
affected by predisposing (age, sex, and race), enabling (marital status, education level, poverty
status, prescription coverage, and fragmented care), need (number of chronic conditions, number
of activities of daily living (ADL), and number of unique medications) factors, personal
healthcare practices (obesity and smoking status) and external environment (e.g. residency
region). For this study, the number of chronic conditions included cancer, diabetes, hypertension,
heart disease, arthritis, and osteoporosis. We calculated fragmented care similar to previous
studies77,78.
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Statistical Analyses
Patient characteristics by asthma/COPD categories were compared using chi-square test
for categorical variables and ANOVA for continuous variables. The unadjusted and adjusted
associations of asthma/COPD categories to economic burden were evaluated using generalized
linear models (GLM). GLM with a gamma distribution and log-link function was used for total
and third-party expenditures and GLM with binomial distribution and log-link function (i.e.
logistic regression) was used to model high OOP burden. The robust estimates of excess burden
of ACO were derived using the counterfactual recycled prediction. Separate models were used
for total healthcare expenditures, third-party expenditures, and OOP expenditures. In all the
models, the reference group was NANC. In the adjusted models, we controlled for predisposing,
enabling, need factors, personal healthcare practices, and external environmental factors.
To estimate the extent to which differences in characteristics of individuals among the
four groups (ACO, asthma only, COPD only, and NANC) contribute to the excess economic
burden we used linear and non-linear decomposition analyses. In these analyses, we distinguish
between explained and unexplained parts of the average difference in an outcome (example: total
healthcare expenditures). The explained part was derived by taking the differences in average
characteristics between two groups and weighting by regression co-efficient estimates from the
pooled regression of fully adjusted model. Unexplained portion was derived from differences in
regression-coefficients of the two groups weighted by average characteristics of groups.
Linear decomposition analysis followed the Blinder-Oaxaca approach for survey data
using pooled regression weights. The decomposition analysis used log-transformed total
healthcare expenditures as the dependent variable and assesses how much of the difference in
log-transformed total healthcare expenditures between groups can be due to difference in
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characteristics (e.g. the predisposing, enabling, need, personal healthcare practices, and external
environmental factors described above). For high OOP burden, we used the non-linear
decomposition technique proposed by Fairlie79. We summarize results from the decomposition
analysis by comparing NANC to: 1) ACO; 2) COPD only and 3) asthma only. All data
management and analyses were conducted with SAS 9.4 (SAS Institute Inc., Cary, NC) and we
used Stata 14 (StataCorp LLC, College Station, TX) for decomposition analyses.
2.4 Results
Sample Description
The study sample consisted of 38,089 person-years and included community-dwelling,
full-year enrolled in fee-for-service Parts A and B, elderly (age > 65 years) Medicare
beneficiaries. (Appendix 7.3) The prevalence of ACO, asthma only, COPD only conditions were
1.5%, 2.4%, and 8.8% respectively between 2006 and 2013. ACO, asthma only, COPD only and
NANC groups were significantly different in terms of all predisposing, enabling, need, personal
healthcare practices, and external factors (Table 2.1). For example, individuals with ACO had
the highest rates of poverty (59.8% vs 44.2%) and higher levels of fragmented care (78.08+
12.01 vs 66.08+ 22.17) and higher number of unique medications (16.12 + 7.27 vs 7.53+ 5.32) as
compared to NANC.
Healthcare Expenditures
The unadjusted and adjusted average annual total healthcare and third-party expenditures
are provided in Figure 1. Average total, third-party and OOP expenditures were significantly
higher for all Asthma/COPD categories compared to NANC. Medicare beneficiaries with ACO
in comparison with NANC had almost 3.5-time higher unadjusted annual average total
healthcare expenditures ($45,532 vs. $12,743), with an excess per patient cost of $32,789 (P
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<0.001). The excess total healthcare expenditures COPD only and asthma only were $17,409
and $10,760 respectively. The excess third-party expenditures for ACO, COPD only and asthma
only were: $31,113, $16,383, and $9,459 respectively. Similar differences were observed in OOP
payments (Figure 1).
Using recycled prediction, we observed that annual total healthcare expenditures
remained significantly higher (Figure 2.1-b) for those with ACO ($22,968), yielding an excess
cost of $7,211 (P <0.001). Adjusted annual third-party payers’ expenditures were significantly
higher ($6,871) for individuals with ACO as compared to NANC. Compared to older adults
with asthma only, individuals with ACO had an excess total healthcare expenditure of $11,505
(P <0.001) and third-party payers’ expenditures of $11,351 (P <0.001). Moreover, individuals
with ACO had $6,504 (P <0.001) excess total healthcare expenditures and $6,273 (P <0.001)
higher third-party payers’ expenditures in comparison with those with COPD only.
Results from the linear decomposition analysis are summarized in Table 2. The average
predicted log-transformed total healthcare expenditures for the ACO group was 10.393 units; the
corresponding figure for NANC was 8.994 units, yielding a difference of 1.399 log-transformed
expenditures. We found that differences in predisposing, enabling, need, personal healthcare
practices, and external factors could explain 77% of this difference in average log-transformed
total healthcare expenditures. Thus, if older adults with ACO were to have similar characteristics
as those with NANC, the difference in log-transformed dollars would reduce to 8.99. Of the
1.399 unit difference, 1.081 units (76.98%) were explained by the differences in characteristics.
The number of unique medications (0.833 units, 77.30%) and fragmented care (16.08 units,
14.93%) were explained by differences in other characteristics.
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Of the total difference in log-transformed costs (1.003) among COPD only and NANC
group, 0.594 units (or 59.21%) was explained by differences in the patient-level characteristics
between the two groups. Similarly, of the total difference in log-transformed expenditures
(0.735) among asthma only and NANC group, 0.655 units (89.21%) was explained by
differences in characteristics between asthma only and NANC groups. In all these comparisons,
number of unique medications, need factors (i.e. number of chronic conditions and number of
ADL) and fragmented care were the leading drivers of the excess economic burden.
High OOP spending burden
Figure 3.2 summarizes the prevalence of high OOP spending burden among the four
asthma/COPD groups; 42% with ACO, 34% with COPD and 29% with asthma reported high
OOP burden as compared to 17% among individuals with NANC. In the unadjusted logistic
regression models, the odds of high OOP spending burden was significantly higher among
individuals with ACO (UOR = 3.51, 95% CI = [2.96, 4.16], P<0.001), asthma only (UOR = 1.99,
95% CI = [1.68, 2.36], P<0.001), and COPD only (UOR = 2.40, 95% CI = [2.20, 2.61], P<0.001)
as compared to the NANC group. In the adjusted logistic regression models, the association
remained significant. The odds of high OOP spending burden was significantly higher among
individuals with ACO (AOR = 3.51, 95% CI = [2.96, 4.16], P<0.001) and COPD only (AOR =
3.51, 95% CI = [2.96, 4.16], P<0.001) as compared to the NANC group.
Based on non-linear decomposition analysis, we found that of the 23.53 percentage point
difference in high OOP burden, 19.59 percentage points were explained by the differences in the
characteristics between the ACO and the NANC group (Table 2.2). Thus, if older adults with
ACO were to have similar characteristics as those of the NANC group, the difference in OOP
burden would be reduced to 18.5 percentage points. Of this total difference, 13.18 percentage
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points (or 67.29%) was explained by the number of unique medications. Similar findings were
observed when asthma only group was compared to NANC and the COPD only group was
compared to NANC.
2.5 Discussion
This study examined the excess economic burden associated with ACO among older
adults in the US, using multiple years of a nationally representative sample of Medicare
beneficiaries. In this study, the overall prevalence of ACO was 1.5%. Although no study has
reported the specific prevalence of ACO among Medicare beneficiaries, this estimate is less than
the 3.8% which was previously reported by Kumbhare et al for (65-85 years old) older adults in
the United States14. Possible explanations of this difference are methods of identification and
time period. While this study used fee-for-service Medicare claims for identification of ACO
during a calendar year, Kumbhare et. Al. used “ever diagnosed” using self-reports. Thus, we
may have captured only older adults who had currently active asthma and COPD and had
diagnoses updated in their medical claims.
In terms of projected total healthcare expenditures, nearly two billion dollars (2013USD)
was spent on the healthcare of older community-dwelling adults with ACO (weighted number of
ACO adults in 2013= 42,984 multiplied by the average per-capita cost $45,532). In terms of the
excess economic burden, individuals with ACO had almost four, two, and 1.5 times higher
expenditures compared to individuals with NANC, asthma only, and COPD only, respectively.
Even after controlling for multiple determinants of expenditures, the presence of ACO was
associated with significantly higher expenditures in comparison with individuals with NANC,
asthma only, or COPD only, consistent with previously published studies that compared per-
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capita expenditures of individuals with ACO to those with asthma only17 or those with COPD
only18.
The excess expenditures associated with ACO is not surprising because studies have
documented increasing expenditures with increasing number of chronic conditions 80.
Furthermore, our finding that ACO patients had higher economic burden compared to those with
asthma only or COPD only may be explained through higher rates of uncontrolled disease states,
respiratory infections, and exacerbations, which may lead to higher expenditures. While
healthcare utilization and reasoning for expenditure was not directly reviewed in this study, a
prior study of 17,088 COPD patients in Taiwan reported that ACO patients experienced almost
twice as many acute respiratory events (e.g. acute respiratory failure, pneumonia, and acute
exacerbation) than did the rest of the COPD cohort12. This higher event rates undoubtedly lead
to higher healthcare resource utilization and overall higher direct costs.
In this study, those with ACO had higher odds of high OOP spending burden compared
to all other groups in both unadjusted and adjusted models. This high burden could be due to
cost-sharing of Medicare-covered services, including prescription drugs and payments for noncovered services by Medicare. OOP burden may be particularly high among individuals with
ACO because of historically high cost-sharing of inhaler medications. Based on data from
nationwide Part D plans, it has been estimated that mean OOP expenditures were $30–$105 per
inhaler in 201564. According to this study, a typical older Medicare beneficiary who use 2-3
inhalers per month have annual OOP expenditures of at least $1,622–$2,81l for their inhalers.
Individuals with ACO may have greater need for some of the services not covered by
Medicare compared to NANC as they are higher risk of these conditions. For example,
individuals with ACO have significantly higher odds (AOR = 1.82, 95% CI = [1.59, 2.08],
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P<0.001) of removing all teeth compared to NANC81, suggesting greater spending on oral
healthcare by patients. It has also been reported that COPD patients are vulnerable to low-value
care82, which may increase OOP spending of families and patients through cost-sharing.
Medicare reform proposals that focus on value-based healthcare that balance the value of health
services to the OOP spending burden of patients (vs. quantity of care) may reduce the excess
economic burden of patients.
The current study used linear and non-linear decomposition analyses to examine the excess
economic burden of chronic respiratory conditions, one of the top four conditions of public health concern
designated by the World Health Organization (WHO)83. The other three conditions are cardiovascular
disease, diabetes, and cancer. It is important to note that older adults with chronic respiratory conditions
also have higher rates of CVD, diabetes, and cancer. A population survey among (>18 years) adults in the
US also found that the adjusted odds of six chronic conditions (e.g. cardiovascular diseases, diabetes, and
depression) is higher in ACO compared to asthma only and COPD only 14. In our study, 91% of ACO
patients had more than two other chronic conditions which was higher than asthma only (89%), COPD
only (87%) and NANC (76%) groups. Our decomposition analysis suggested that patient-level
characteristics such as higher number of co-existing chronic conditions and related characteristics (i.e.,
higher number of unique medications and higher levels of fragmented care) were the leading drivers of
the excess economic burden among ACO patients. For example, receiving care from several different
providers often results in gaps in communication between providers which can lead to suboptimal care
and polypharmacy75,84. Prior studies suggest that more fragmented care is associated with more diagnostic
tests, more low-value care, and lower patient satisfaction85–87. Previous studies further suggest the
associations of fragmented care and higher number of emergency department (ED) visits, higher
hospitalization rates, and higher expenditures77,88.
Taken together, our study findings highlight the need for a “holistic management” of older adults
with chronic respiratory conditions, specifically ACO, asthma, and COPD. Given that those with chronic
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respiratory conditions may need to see multiple providers and have a high medication burden, the risks of
fragmented care and drug-disease and drug-drug interactions are very high. These factors often lead to
greater economic burden, as evidenced by our study. Although the CMS began reimbursing providers for
providing coordinated care for those with multiple conditions in 201589, it remains to be seen whether
such fiscal incentives for care coordination have resulted in less fragmented care and reduced healthcare
expenditures. In this context, patients with chronic respiratory conditions (ACO, asthma, and COPD) may
need to be managed in a patient-centered medical home model which focuses care that is “comprehensive,
team-based, coordinated, accessible, and focused on quality and safety.” 90. As documented in published
literature, pharmacists can play an important role in medical homes by reducing unnecessary medications,
counseling patients and/or caregivers, reviewing medication regimens and inhaler techniques, and
completing adherence assessments91–93. Such management may improve not only outcomes but also lower
the economic burden of patients, payers, and health systems.
Summarily, our findings have policy and program implications. Our study findings highlight the
need to develop guidelines for the management of overlapping chronic conditions. Applying “singledisease focused” clinical practice guidelines can result in missing or inappropriate therapies and adverse
drug-drug and drug-disease interactions. A systematic review of recommendations in 12 UK national
clinical guidelines notes that potentially serious drug-drug interactions were common94. Adherence to
guidelines intended for single-diseases in those with multiple chronic conditions can also generate more
low-value care and lead to higher healthcare expenditures the patient, payors, and the society as holistic,
big-picture care may be lacking 95,96.

2.6 Limitation
As with most studies, this study also had some limitations. The first limitation was the
lack of availability of data from recent years. Notwithstanding this limitation, we used the most
recently available data of a nationally representative large sample of elderly Medicare
beneficiaries. Another limitation was the lack of information on the onset and severity of
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diseases. To overcome this, we used ADL status as a proxy of overall severity of diseases.
Furthermore, the findings of the current study cannot be generalizable to all older adults in the
US, although it is generalizable to the majority of older adults (community-dwelling Medicare
beneficiaries enrolled in fee-for-service Part A and B).
2.7 Conclusion
This study is the first to document the excess economic burden of ACO among elderly
Medicare beneficiaries. ACO among elderly Medicare beneficiaries was associated with
substantial total healthcare expenditures, third-party payers’ expenditure and high OOP spending
burden, even after adjusting with a comprehensive list of variables. Post regression
decomposition analyses revealed that the challenges associated with multiple chronic conditions,
specifically use of multiple medications and high levels of fragmented care were the leading
drivers of the excess economic burden. Individual, policy, and program interventions that
facilitate coordination of care may reduce the excess economic burden of older adults with
chronic respiratory conditions, specifically ACO, asthma, or COPD.
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ALL
Sex

Table 2.1.
Unweighted N and Weighted Percentages of Characteristics by Asthma /COPD Categories (Column %)
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
Asthma-COPD
Neither Asthma
Asthma only
COPD only
Overlap
Nor COPD
N
Wt. %
N
Wt. %
N
Wt. %
N
Wt. %
589
1.5
860
2.4
3,518
8.8
33,122
87.3

Sig

***
Female
389
67.0
658
77.6
1,719
49.7
18,703
56.1
Male
200
33.0
202
22.4
1,799
50.3
14,419
43.9
Age in Years
***
65-74
205
39.5
397
53.7
1,215
40.9
13,290
48.1
75-84
270
44.1
323
34
1,642
43.7
13,413
36.8
85 and above
114
16.4
140
12.3
661
15.4
6,419
15.1
Race/Ethnicity
***
White
451
76.7
663
78.3
3,044
86.7
27,371
82.6
Black
47
8.0
85
9.5
168
4.7
2,303
6.8
Latino
48
7.6
60
6.5
146
4.0
1,891
5.9
Other race
42
7.7
52
5.7
153
4.6
1,486
4.8
Marital Status
***
Married
224
39.3
405
48
1,690
49.3
17,456
55.2
Not married
364
60.7
454
52
1,824
50.7
15,656
44.8
Education
Less than high school
194
31.6
178
19.3
1,150
31.7
7,734
21.3
***
High school
218
37.8
287
31.3
1,284
36.4
11,962
35.6
Above high school
175
30.6
393
49.4
1,072
31.9
13,295
43.1
Poverty Status
***
Less than 200% FPL
364
59.8
415
44.9
2,077
57.7
15,526
44.2
At least 200% FPL
225
40.2
445
55.1
1,441
42.3
17,596
55.8
Prescription Coverage
***
Yes
414
70.6
590
67.0
2,299
65.2
20,397
60.9
No
175
29.4
270
33.0
1,219
34.8
12,725
39.1
% Fragmented Care
78.08† 12.01‡ 75.06†
14.65‡ 73.88† 16.62‡
66.80† 22.17‡
***
# Other Chronic Conditions
***
0-1
53
9.0
93
11.0
419
13.0
7,122
23.6
2-3
273
47.6
471
56.4
1,754
50.7
17,539
53.4
4-6
250
43.3
285
32.6
1,272
36.3
8,035
23.0
# ADL
***
0
269
45.4
544
64.5
1,830
52.8
23,532
73.4
1-2
192
34.0
213
25.0
1,096
31.0
6,683
19.0
3-6
123
20.6
102
10.5
573
16.2
2,793
7.6
# Unique Medications
16.12†
7.27‡ 12.73†
6.29‡ 12.57†
6.75‡
7.53†
5.32‡
***
Obesity
***
Yes
207
38.5
298
36.5
897
26.8
7597
24.0
No
381
61.3
550
62.1
2588
72.2
25207
75.0
Smoking Habit
***
Current/Past
429
73.7
410
48.7
2943
84.4
18256
56.0
Never
154
25.3
449
51.2
556
15.0
14762
43.7
Residency Region
***
Northeast
118
23.3
170
22.6
578
17.9
5,115
17.3
South
126
20.4
189
21.8
873
23.8
8,321
23.9
Midwest
250
39.5
355
38.3
1,668
46.3
14,104
40.3
West
95
16.9
146
17.4
399
11.9
5,582
18.4
Note: Based on 38,089 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in
fee-for-service Part A and Part B during the calendar year and alive during the calendar year.
Significant group differences in asthma-COPD status were based on Rao-Scott chi-square tests. ANOVA test was used for number of
unique medications and % fragmented care.
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ADL: Activities of Daily Living; FPL: federal poverty level; N: unweighted number; Sig: significance; Wt: weighted; %: Percentage;
†: Mean; ‡: Standard Error; ***p<.001, ; **.001 ≤ p < .01; *.01 ≤ p <.05
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Figure 2.1.
Total Healthcare Expenditures and High Out-of-Pocket Burden by Asthma/ COPD Categories
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013

Note (a) Unadjusted expenditures, (b) Adjusted expenditures from recycle prediction” group, (c) high OOP spending burden percentage
(d) Unadjusted and adjusted odds ratio of high OOP spending burden by asthma/COPD categories
Based on 38,089 elderly Medicare beneficiaries who were observed between years 2006 and 2013. The variables in the adjusted models
were selected based on Andersen’s healthcare behavioral model and include sex, age, race, marital status, poverty, education,
prescription coverage, fragmented care, # ADL, # chronic conditions, # unique medications, overweight, smoking habit, and residency
region.
Abbreviations: ADL: Activity Daily Limitation; COPD: chronic obstructive pulmonary disease; OOP: Out-of-Pocket; Log: natural
logarithm; #: number; $: Dollar; %: Percentage; +: Excess cost comparing to no-asthma no-COPD;
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Table 2.2
Post-Regression Decomposition Analyses
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
Decomposition of Log Total Healthcare Expenditures (2013US$) by Asthma/COPD Categories
by Using Blinder Oaxaca Liner Decomposition analysis for survey Data using Pooled Regression Weights
Asthma COPD Overlap
Asthma Only
COPD Only
Average Log Total Healthcare Expenditures
10.3935
9.7287
9.9944
Average Log Total Expenditures of “neither asthma nor COPD” group
8.9941
8.9941
8.9940
Difference in Log Total Healthcare Expenditures
1.3994
0.7346
1.003
Total “explained” percentage
76.98%
89.21%
59.21%
% Contribution to the “Explained” Portion
Asthma COPD Overlap
Asthma Only
COPD Only
Predisposing characteristics (sex, age, race)
-1.51%
-6.28%
3.17%
Enabling factors 1 (marital status, poverty, education, prescription coverage)
-2.00%
1.18%
-3.70%
Enabling factor 2 (fragmented care)
14.93%
18.04%
19.58%
Need Factors 1 (# ADL, # chronic conditions)
11.84%
7.16%
15.16%
Need Factors 2 (# unique medications)
77.30%
79.60%
66.52%
Personal healthcare practice (obesity, smoking)
-0.85%
-1.64%
0.08%
External factors (residency region)
0.29%
1.94%
-0.81%
Decomposition of High OOP spending burden by Asthma/COPD Categories
by Using Fairlie’s Non-Linear Decomposition for Weighted Data
Asthma COPD Overlap
Asthma Only
COPD Only
Probability of having high OOP spending burden
0.4204
0.2925
0.3336
Probability of having high OOP spending burden of “neither asthma nor COPD”
group
0.1850
0.1850
0.1850
Differences in probability of high OOP spending burden
0.2353
0.1075
0.1486
Total “explained” percentage
83.24%
89.17%
71.67%
% Contribution to the “Explained” Portion
Asthma COPD Overlap
Asthma Only
COPD Only
Predisposing characteristics (sex, age, race)
-1.40%
-2.80%
-0.41%
Enabling factors 1 (marital status, poverty, education, prescription coverage)
15.97%
3.45%
20.26%
Enabling factor 2 (fragmented care)
5.65%
8.54%
5.96%
Need Factors 1 (# ADL, # chronic conditions)
11.55%
6.94%
11.73%
Need Factors 2 (# unique medications)
67.29%
82.72%
62.64%
Personal healthcare practice (obesity, smoking)
0.21%
-0.30%
0.55%
External factors (residency region)
0.73%
1.46%
-0.74%
Notes: Based on 38,089 felderly Medicare beneficiaries who were observed between years 2006 and 2013. The percent differences of domains of Andersen’s healthcare behavior
model are illustrated in the model.
Abbreviations: ADL: Activities of Daily Living; COPD: chronic obstructive pulmonary disease; OOP: Out-of-Pocket; Log: natural logarithm; #: number; $: Dollar; %:
Percentage.
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CHAPTER 3
3 Asthma-Chronic Obstructive Pulmonary Disease Overlap and Cost-Related Medication
Nonadherence among Older Adults in the United States
3.1 Abstract
Objective: Cost-related medication non-adherence (CRN) can negatively impact health
outcomes in older adults with asthma-chronic obstructive pulmonary disease (COPD) overlap
(ACO) by reducing access and adherence to essential medications. The objective of this study is
to examine the association of ACO to any CRN and specific forms of CRN among a nationally
representative sample of older (age > 65 years) adults.
Methods: We adopted a cross-sectional study design using data from pooled cross-sectional
Medicare Current Beneficiary Surveys (2006-2013) and linked fee-for-service Medicare claims.
Unadjusted and adjusted logistic regressions that accounted for the complex survey design
examined the association of ACO to any CRN and specific forms of CRN.
Results: Among older adults with ACO, 16% reported any CRN. The most common form of
CRN was “failing to get prescription”. As compared to older adults with no asthma and no
COPD, those with ACO were more likely to report any CRN (AOR = 1.50, 95%CI= [1.14,
1.96]) and all forms of CRN. However, when the number of unique medications were added to
the model, there were no statistically significant differences in CRN between the two groups.
Conclusions: Older adults with ACO represent a vulnerable population with increased risk for
CRN. Multiple factors can contribute to CRN including: a higher number of prescribed
medications, multiple co-morbidities, and cost of therapies. Deprescribing – as appropriate – is
an opportunity and process which could reduce the risk of CRN among the older Medicare
beneficiaries with ACO.
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3.2 Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are the two most common respiratory
diseases worldwide. Combined, more than 435 million adults suffer from asthma and COPD1,2. In many
cases where airway obstruction is noted, asthma and COPD can coexist as “Asthma-COPD overlap”
(ACO), which can be as high as 50% among elderly (age > 80 years) patients with either asthma or
COPD10. Treatment for both asthma and COPD focuses on symptom management rather than clinical
cure; similarly, ACO is managed with pharmacotherapy recommended in both disease states. Adherence
is critical in ACO as therapy is primarily maintenance therapy (i.e. taken daily) versus as needed to
maximize effects on reducing inflammation, bronchoconstriction, and sputum production.

20,97.

However,

studies demonstrate many individuals with either asthma or COPD do not adhere to prescribed
medication regimens with non-adherence rates often >20%26,29,30. While many factors influence
medication adherence, older adults with chronic conditions often report cost-related barriers as a reason
for medication nonadherence 98–102. High out-of-pocket (OOP) prescription costs can overwhelm some
older adults compelling them to adopt cost-coping strategies103 such as (1) failing to fill a prescription; (2)
delaying filling prescriptions; (3) skipping medication doses; and (4) using less than prescribed doses of
a medication104.
Although there are no published studies on cost-related non-adherence (CRN) among older adults
with ACO, it is expected that ACO individuals may be particularly vulnerable to CRN based on studies
focusing on either asthma or COPD. In a 2004 study of disease-specific rates of CRN by Piette et al105,
asthma and COPD were among diseases with the highest rates of CRN. Castaldi et al estimated that over
one third of older adults with chronic pulmonary diseases reported CRN32. However, this study did not
compare the risk of CRN for different types of chronic pulmonary diseases including ACO.
Insight into the association of CRN to ACO is important because CRN has downstream effects and
can lead to higher healthcare utilization76, morbidity98, and mortality106. Information on contributors to
CRN among adults with ACO can be used to develop a portfolio of programs targeting these contributors
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and subsequently help improve adherence and reduce the risk of mortality and morbidity among older
adults with ACO.
Therefore, our primary objective was to assess the association of ACO to CRN as compared to
no-asthma and no-COPD and explore the factors that may affect the association of ACO to CRN among
older adults (age > 65 years), using a nationally representative sample of Medicare beneficiaries in the
US.

3.3 Methods
Study Design
We adopted a cross-sectional study design with data from the annual Medicare Current
Beneficiary Survey (MCBS) from 2006 through 2013.
Data Source
The data sources for this study were the Medicare Current Beneficiary Survey (MCBS) and
fee-for-service Medicare claims that are linked to the survey respondents. The MCBS is a
rotating panel survey of a nationally representative sample of the Medicare population and has
been carried out since 1991. The goals of the survey are to collect information on healthcare
access, expenditures, sources of payment, health outcomes, health status, and satisfaction with
care of Medicare beneficiaries51. To improve the accuracy and completeness of healthcare use
and costs, survey data are matched, reconciled, and supplemented with fee-for-service Medicare
claims creating the best of both survey and claims data worlds49.
From 1992 to 2013, the MCBS released two data files, the “Access to Care” (AC) and the
“Cost and Use” (CU) files, annually. While both AC and CU files include some common
elements, AC files provide additional information on access to care, information needs, patientprovider relationships, and satisfaction with care on “always enrolled” Medicare beneficiaries.
CU files include detailed data on reconciled cost and use information on “ever enrolled”
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Medicare beneficiaries 51. Medicare claims have information on all reimbursed healthcare
encounters of fee-for-service Medicare beneficiaries including International Classification of
Diseases 9th Edition (ICD-9) codes, payments, procedures, and other treatments.
For this study, we used AC and CU files and fee-for-service Medicare claims from 2006 to
2013. We selected these years because of the introduction of Medicare Part D program
beginning in 2006. We used AC files to capture information on CRN. We used CU files for
deriving other variables. We identified asthma-COPD status by using fee-for-service inpatient,
outpatient, physician, and home healthcare Medicare claims files.
Study Sample
The study sample included community-dwelling elderly (age > 65 years) Medicare
beneficiaries who were enrolled in fee-for-service (Parts A and B) during the calendar year and
alive throughout the calendar year. We further restricted our study sample to those with
available information in both AC and CU files of the MCBS and those without missing data for
CRN measures (N = 37,571). (Appendix 7.7)
Measures
Dependent Variable: Any CRN (Yes/No) and Specific Forms of CRN
In MCBS, four questions queried CRN-related behaviors. The validity and reliability of
using these questions for measuring CRN have been confirmed in previous studies 107–109.
Respondents were asked, “Please tell me how often during (CURRENT YEAR) you did any of
the following behaviors (1) decided not to fill a prescription because it cost too much, (2)
delayed getting a prescription filled because the medicine cost too much, (3) skipped doses to
make the medicine last longer, (4) taken smaller doses of a medicine to make the medicine last
longer”. The answers were recorded on a 3-point scale (often, sometimes, and never). If
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respondents answered “often or sometimes” to any of these questions, the respondents were
considered to have any CRN, and those who responded never to all the questions were
considered to have no CRN. For all specific forms of CRN, we combined “often” and
“sometimes” to create indicator variables (Yes/No).
Key Independent Variable: Asthma and COPD categories
The key independent variable was asthma-COPD status. The first step of preparing this variable
was identification of individuals with either asthma or COPD by using the ICD-9 codes available in
Medicare claims (Appendix 7.2). These diagnosis codes for asthma and COPD have been utilized in
previously published research73,74. Individuals with at least one inpatient visit or two outpatient visits (at
least 14 days apart) for either asthma or COPD codes were considered to have diagnosed asthma or
COPD. Based on the presence of asthma or COPD, we created the following four categories: 1) Asthma
and COPD (ACO); 2) Asthma without COPD; 3) No asthma with COPD; and 4) No asthma and No
COPD.

Other independent Variables
We used Anderson’s health behavior model as well as published literature to guide the
selection of other independent variables associated with CRN. We selected Andersen behavior
model for this study as it gives us a comprehensive list of factors associated with CRN. Per the
framework, CRN may be affected by: 1) pre-disposing variables (Sex (Male/female); age (6574/75-84/ 85 years or older); race/ethnicity (White/Black/Hispanic/or other races)); 2) enabling
factors (marital status (married/not married); education level (less than high school/high
school/and above high school); poverty status [based on income relative to the level of federal
poverty line (FPL)] (< 200% of FPL>= 200% of FPL)); high burden of OOP prescription cost
([annual OOP prescription costs > annual 10% of income] (yes/no); high burden of OOP medical
costs [annual OOP medical costs > annual 10% of income] (yes/no); and prescription drug
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coverage (yes/no)); 3) need factors (the number (1-6) of chronic conditions (cancer, diabetes,
hypertension, heart disease, arthritis, and osteoporosis)); the number of unique medications;
personal health practices (obesity status (yes/no); and smoking status (neversmoker/former/current smoker).
Statistical analyses
Unadjusted group differences in terms of asthma-COPD status were tested with RaoScott Chi-square tests. We used separate logistic regression models to examine the unadjusted
and adjusted associations between asthma-COPD status and CRN (i.e. any CRN and specific
forms of CRN). Results are presented in terms of unadjusted (UOR) and adjusted odds ratios
(AOR) and 95% confidence intervals (CI). All analyses utilized the SURVEY procedures of
Statistical Analysis Software (SAS®) version 9.4 to account for the complex survey design of
MCBS.
3.4 Results
The study sample consisted of 37,571 person-years and included elderly (age > 65 years)
community-dwelling, full-year fee-for-service Parts A and B Medicare beneficiaries, without
missing data on CRN measures between 2006 and 2013. (Appendix 7.8) The overall prevalence
of ACO, asthma-only, and COPD-only was 1.5%, 2.3%, and 8.8% respectively during the study
period.
There were significant differences between asthma-COPD status groups in terms of sex,
age, race/ethnicity, marital status, education level, poverty status, prescription coverage, high
burden of prescription cost, high burden of medical cost, the number of chronic conditions, and
number of unique medications (Table 3.1). For example, individuals with ACO have the highest
rates of high burden of OOP prescription costs (9.3%) and OOP medical costs (28.3%) compared
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to individuals with asthma-only (6.2% & 17.1%), COPD-only (9.0% & 20.9%), and no-asthma
no-COPD (4.0% and 11.0%). The number of unique medications was the highest among
individuals with ACO (16.21+0.34) compared to those with asthma-only (12.74+0.29), COPDonly (12.51+0.17), and no-asthma no-COPD (7.37+0.06).
Unadjusted and Adjusted Associations of ACO to any CRN
The prevalence of any CRN was 9.7% among older Medicare beneficiaries. Individuals
with ACO had the highest percentage of any CRN (16.0%) compared with individuals with
asthma-only (14.5%), COPD-only (13.0%), and no-asthma no-COPD (9.1%) (Figure 3.1).
Compared to individuals with no-asthma no-COPD, individuals with ACO (UOR = 1.89, 95%
CI = [1.45, 2.45]) were more likely to report CRN (Table 3.2). In models without adjustments
for number of unique medications, individuals with ACO were more likely to report (AOR =
1.50, 95% CI = [1.14, 1.96]) any CRN compared to individuals with no-asthma no-COPD (Table
2). In the fully adjusted model for any CRN, those with ACO were as likely as those with no
asthma and COPD to report CRN (AOR = 1.23, 95% CI = [0.92, 1.63], p = 0.15).
Association of ACO to specific forms of CRN
Those with ACO had the highest percentages of three specific forms of CRN including:
failing to fill prescription (10.1%), delaying filling prescription (7.9%), and skipping medication
doses (6.9%) (Figure 3.1). In the unadjusted and adjusted models, without number of unique
medications, individuals with ACO had higher odds of “failing to fill prescription”, “delaying
filling prescriptions”, and “skipping medication doses”, compared with individuals with noasthma no-COPD (Table 3.3).
In the fully adjusted model that included the number of medications as one of the
independent variables, those with ACO (AOR = 1.43, 95% CI = [0.99, 2.07], p = 0.05), had
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marginally higher odds of “failing to fill prescription” compared to those with no asthma and no
COPD. In the fully adjusted models for other specific forms of CRN, we did not observe
statistically significant differences among adults with ACO and adults with no asthma and no
COPD.
Comparison ACO with asthma-only and COPD-only groups
Comparisons were also made among asthma or COPD categories (asthma only, COPD
only). As indicated in Table 3.2, we also used COPD-only or asthma-only as reference groups.
In all the models, there were no statistically significant group differences among asthma only,
COPD only, and ACO.
3.5 Discussion
One in six older Medicare beneficiaries with ACO reported any CRN between 2006 and
2013. The most prevalent form of CRN was “failing to fill prescription,” which was almost twice
as high among Medicare beneficiaries with ACO compare to those with no-asthma and noCOPD.
Older adults with ACO were more likely to report any CRN compared to older adults
with no-asthma no-COPD; while not directly studied, this likely has significant later-in-life
morbidity and mortality consequences76,98. This is not surprising because older adults who had
high OOP burden compared to those with neither asthma nor COPD and high OOP burden was
significantly associated with CRN. The high OOP burden among adults with ACO can be
explained by the high cost of brand-name inhaler therapies and the high medication burden per
individualized regimen to adequately manage ACO (often 2 to 3 inhaler therapies). Although,
we did not distinguish between asthma and COPD-related medications, we speculate that those
with ACO need to use inhalers for the management of ACO, as these are first line therapy per the
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most recent guidelines110. The cost of inhalers dramatically increased in 2008, after the banning
of chlorofluorocarbon propellants111. This led to phasing out generic inhalers, leaving only
maintenance, brand-name inhalers112. A study by Tseng et al indicated that although inhalers
were universally covered by Medicare Part D plans, it required high cost-sharing by Medicare
beneficiaries64. This can be seen as patients experience higher annual plan deductibles and
elevated copay costs (inhalers are often included in higher tiers of formularies because of their
brand status) despite Medicare covering a portion of the prescription. For instance, using a
single inhaler each month had projected annual OOP costs of $900 under a standard Part D plan
in 201564. Our study findings suggest that policy makers may need to re-evaluate coverage of
inhalers under Part D plans.
In our study, increased risk of any CRN among ACO individuals compared to those with
no-asthma or no-COPD is apparent by adjusting all factors without number of unique
medications. However, the inclusion of number of unique medications attenuated this
association, suggesting that number of medications may be a key link between ACO and CRN.
Notably, the mean number of unique medications is approximately 16 among individuals with
ACO which is significantly higher compared to individuals with asthma-only (~13), COPD-only
(~12.5), and no-asthma no-COPD (~7). Individuals with ACO have a higher number of unique
medications due to two following reasons: (1) individuals with ACO may need to use a higher
number of respiratory medications to adequately control respiratory symptoms. The Latin
American Project for the Investigation of Obstructive Lung Disease (PLATINO) study found
that 49% of individuals with ACO used respiratory medications significantly higher than
individuals with asthma-only (38%) or COPD-only (20%)13; (2) ACO individuals may need to
use a greater number of non-respiratory medications due to higher risk of comorbid medical
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conditions. In our study, 43% of ACO individuals had 4-6 other chronic conditions, while this
number was lower among individuals with asthma-only (33%), COPD-only (36%), and noasthma no-COPD (23%). A population survey in the US similarly found that 90% of individuals
with ACO had at least one other co-existing condition (compared with 71% in asthma-only and
84% in COPD-only)14.
Taken together, all these findings suggest that reducing the number of medications may
directly reduce the likelihood of CRN, and indirectly alleviate the high burden of OOP
prescription cost among older adults with ACO. As documented in published literature,
clinicians and pharmacists can play an important role in deprescribing unnecessary medications.
For example, during annual wellness visits, now covered by Medicare, a comprehensive review
of medications can be performed and highlight opportunities for prescription regimen
optimization113. Providers can proactively participate in deprescribing by: 1) discontinuing
unnecessary therapy, 2) discontinuing duplicate therapies, 3) combining therapies as appropriate
(i.e. combination inhalers), and 4) replacing high-cost therapies with more affordable options. In
a survey of elderly Medicare beneficiaries, more than 30% of individuals reported they did not
have the chance of talking with their provider about their medications in the last 12 months 114.
Intensive, chronic care management can be optimized through team-based care.
Another possible strategy to reduce number of medications is using non-pharmacological
approaches such as lifestyle modification instead of prescribing medication. The Trial of
Nonpharmacologic Interventions in the Elderly demonstrated that reduced sodium intake and
weight loss could help discontinuation of antihypertensive medications in almost 40% of the
intervention group115,116. In addition to previous strategies, "time to benefit" (TTB) in relation to
medication prescribing for older patients with multi-comorbidities can be utilized 117. TTB is a
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measurement of the time to significant observable benefit in randomized clinical trials of a
medication compared with controls. This type of information is not routinely available. In the
future, this may help guide clinicians to discontinue some medication prescriptions for older
individuals when up-titration of a regimen was quicker than TTB.
Strengths and Limitations
To date, ours is the first study to examine the association between ACO and CRN among
a nationally representative sample of fee-for-service community-dwelling Medicare
beneficiaries. Medicare claims enabled us to identify current asthma and COPD status. Survey
data provided the opportunity to control for a comprehensive set of covariates that are otherwise
not available in claims data.
This study also has some limitations. Many variables in this study including CRN are
self-reported, which may be subject to recall bias and social desirability bias. The findings of this
study are not generalizable to all elderly Medicare beneficiaries as Medicare HMO enrollees or
institutionalized beneficiaries were not included in this study. Despite the benefits of linked
survey modules with claims, information about the age of onset, and the severity of ACO,
asthma, COPD were not available in the dataset. Another limitation of this study is that CRN
measures are for all types of medications and not for a specific medication group (e.g. inhalers).
Finally, the study design is a cross-sectional study which makes it hard to establish a cause and
effect relationship. Future cohort studies may help to evaluate the association between ACO and
CRN.
3.6 Conclusion
CRN remains an issue among elderly Medicare beneficiaries. Individuals with ACO are
vulnerable for any CRN and its specific forms. The high number of medications used among
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ACO individuals explained the association of ACO to CRN. Interventions which target reducing
therapy burden and cost are needed to reduce CRN and prevent downstream effects of
medication nonadherence in patients with ACO.
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ALL
Sex

Table 3.1
Unweighted N and Weighted Percentages of Characteristics by
Asthma and Chronic Obstructive Pulmonary Disease (COPD) Status (Column %)
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
AsthmaNeither-Asthma
COPD
Asthma-Only
COPD-Only
Nor-COPD
Overlap
N
Wt. %
N
Wt. %
N
Wt. %
N
Wt. %
576
1.5
849
2.3
3,446
8.8
32,700
87.4

Female
Male
Age in Years
65-74
75-84
85 and above
Race/Ethnicity
White
Black
Latino
Other race
Marital Status
Married
Not married
Education
Less than high school
High school
Above high school
Poverty Status
Less than 200% FPL
At least 200% FPL
Prescription Coverage
Yes
No
High Burden of OOP Prescription Cost
Yes
No
High Burden of OOP Medical Cost
Yes
No
Number of Other Chronic Conditions
0-1
2-3
4-6
Number of Medications

Sig

***
382
194

67.4
32.6

650
199

77.7
22.3

1,686
1,760

49.7
50.3

18,468
14,232

56.1
43.9

205
261
110

40.3
43.5
16.1

391
318
140

53.5
33.9
12.6

1,199
1,605
642

41.2
43.6
15.2

13,098
13,263
6,339

48.0
36.9
15.1

444
46
48
37

77.2
8.0
7.8
7.0

655
84
59
51

78.6
9.3
6.5
5.7

2,982
164
142
151

86.7
4.7
3.9
4.7

27,049
2,269
1,863
1,449

82.7
6.8
5.8
4.7

220
355

39.5
60.5

401
447

48.1
51.9

1,658
1,786

49.3
50.7

17,228
15,462

55.2
44.8

191
211
172

31.7
37.4
30.8

174
286
387

19.1
31.8
49.2

1,131
1,264
1,040

31.8
36.7
31.5

7,649
11,812
13,112

21.3
35.6
43.1

357
219

59.8
40.2

411
438

45.1
54.9

2,036
1,410

57.7
42.3

15,316
17,384

44.2
55.8

405
171

70.7
29.3

582
267

66.8
33.2

2,250
1,196

65.2
34.8

20,143
12,557

60.9
39.1

55
521

9.3
90.7

55
794

6.2
93.8

320
3,126

9.0
91.0

1,375
31,325

4.0
96.0

171
405

28.3
71.7

149
700

17.1
82.9

740
2,706

20.9
79.1

3,825
28,875

11.0
89.0

53
273
250
16.2
1†

9.0
47.6
43.3
0.34‡

93
471
285
12.74†

11.0
56.4
32.6
0.29‡

419
1,754
1,272
12.51†

13.0
50.7
36.3
0.17‡

7,122
17,539
8,035
7.37 †

23.6
53.4
23.0
0.06‡

***

***

***

***

***

***

***

***

***

***

Calendar Year
2006
86
13.2
122
12.7
504
13.2
4,982
13.2
2007
72
10.6
120
13.0
493
12.6
4,636
12.3
2008
81
12.2
97
9.9
460
11.8
4,266
11.7
2009
64
11.1
93
11.0
407
11.9
3,701
11.4
2010
56
10.6
94
12.4
392
12.4
3,459
11.3
2011
82
15.5
115
14.1
404
13.2
3,980
13.4
2012
66
12.3
109
13.8
406
12.5
3,965
13.3
2013
69
14.6
99
13.3
380
12.6
3,711
13.3
Note: Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in
fee-for-service Part A and Part B during the calendar year and alive during the calendar year, and had information in both cost and use
and access to care files.
Significant group differences in asthma-COPD status were based on Rao-Scott chi-square tests. ANOVA test was used for number of
unique medications.
FPL: federal poverty level; N: unweighted number; Sig: significance; Wt: weighted; †: Mean; ‡: Standard Error; ***p<.001
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Table 3.2
Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from
Separate Logistic Regressions on Any Cost-related Medication Nonadherence
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
Ref= No Asthma No COPD
Ref= Asthma Only
Ref= COPD Only
UOR

95% CI

Sig

UOR

1.89

[ 1.45 , 2.45]

***

1.11

1.69

[ 1.34 , 2.14]

***

Ref

COPD only

1.45

[ 1.26 , 1.67]

***

0.86

[ 0.65 , 1.13]

No Asthma No COPD

Ref

0.59

[ 0.47 , 0.75]

***

0.69

[ 0.60 , 0.79]

***

AOR

95% CI

Sig

AOR

95% CI

Sig

1.19

[ 0.88 , 1.61]

1.10

[ 0.84 , 1.43]

Unadjusted Models
Asthma COPD
Overlap
Asthma Only

AOR

95% CI

Sig

95% CI

Sig

[ 0.78 , 1.59]

1.26

No Asthma No COPD

Ref

Fully Adjusted Models
Asthma COPD
Overlap
Asthma Only

[ 1.09 , 1.45]

**

0.91

[ 0.70 , 1.18]

0.72

[ 0.57 , 0.91]

[ 0.70 , 1.44]

95% CI

1.30

[ 0.96 , 1.76]

1.17

[ 0.89 , 1.53]

Sig

Ref

Adjusted Models with All Factors except Number of unique medications
Asthma COPD
1.50
[ 1.14 , 1.96]
**
1.08
[ 0.76 , 1.54]
Overlap
Asthma Only
1.38
[ 1.09 , 1.75]
**
Ref
COPD only

UOR

Ref
**

0.79

[ 0.69 , 0.92]

1.10

[ 0.80 , 1.50]

1.10

[ 0.84 , 1.43]

1.23

[ 0.92 , 1.63]

1.00

1.22

[ 0.97 , 1.54]

Ref

COPD only

1.12

[ 0.96 , 1.30]

0.91

[ 0.70 , 1.19]

Ref

No Asthma No COPD

Ref

0.81

[ 0.65 , 1.02]

0.90

**

[ 0.77 , 1.04]

Note: Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in
fee-for-service Part A and Part B during the calendar year and alive during the calendar year, and had information in both cost and use
and access to care files.
COPD: Chronic Obstructive Pulmonary Disease; CRN: Cost-related Medication Non-Adherence; Ref: reference group; Sig:
significance
***p< .001; **.001 ≤ p < .01; *.01 ≤ p <.05
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Table 3.3
Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from
Separate Logistic Regressions on Specific Forms of CRN
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
Fully Adjusted Models
Unadjusted Models
without Number of unique
Fully Adjusted Models
medications
AO
AO
UOR
95% CI
Sig
95% CI
Sig
95% CI
Sig
R
R
CRN by Using Smaller Doses
Asthma COPD
1.54
[ 0.98 , 2.43]
Overlap
1.21
[ 0.75 , 1.94]
0.97
[ 0.60 , 1.58]
**
1.72
[
1.16
,
2.55]
Asthma Only
1.42
[ 0.95 , 2.10]
1.24
[ 0.83 , 1.84]
[ 1.23 , 1.82]

***

[ 1.41 , 3.31]

***

[ 1.09 , 2.40]

*

COPD only
No asthma and No
COPD
CRN by Failing to Fill Prescription
Asthma COPD
2.25
Overlap
1.61
Asthma Only

[ 1.32 , 1.91]

***

[ 1.59 , 3.17]

***

[ 1.20 , 2.15]

1.65

COPD only

1.49

No asthma No COPD
CRN by Skipping Medication Doses
Asthma COPD
2.16
Overlap
1.62
Asthma Only
1.59

COPD only

No asthma No COPD
CRN by Delaying Filling Prescription
Asthma COPD
2.07
Overlap
1.79
Asthma Only
COPD only

1.69

1.25

[ 1.02 , 1.52]

*

1.10

[ 0.89 , 1.37]

1.58

[ 1.00 , 2.50]

*

1.36

[ 0.87 , 2.11]

1.28

[ 0.87 , 1.87]

1.16

[ 0.79 , 1.70]

1.31

[ 1.09 , 1.58]

**

1.20

[ 1.00 , 1.46]

1.75

[ 1.24 , 2.47]

**

1.43

[ 0.99 , 2.07]

**

1.30

[ 0.97 , 1.73]

1.15

[ 0.87 , 1.52]

[ 1.42 , 1.92]

***

1.41

[ 1.20 , 1.66]

***

1.25

[ 1.05 , 1.49]

[ 1.47 , 2.93]

***

1.48

[ 1.02 , 2.14]

*

1.26

[ 0.87 , 1.81]

[ 1.30 , 2.46]

***

1.37

[ 0.99 , 1.90]

1.24

[ 0.89 , 1.71]

[ 1.37 , 2.09]

***

1.41

[ 1.14 , 1.74]

1.28

[ 1.02 , 1.60]

**

*

*

No Asthma and COPD
Note: Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in
fee-for-service Part A and Part B during the calendar year and alive during the calendar year, and had information in both cost and use
and access to care files.
CI: Confidence Interval; COPD: Chronic Obstructive Pulmonary Disease; CRN: Cost-related Medication Non-Adherence; Sig:
significance
***p< .001; **.001 ≤ p < .01; *.01 ≤ p <.05
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Figure 3.1
Prevalence of any CRN and Specific Types of CRN
By Asthma-COPD Status (i.e., Asthma-COPD Overlap, Asthma-Only, COPD-Only, Neither Asthma nor COPD)
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013

16.0%

14.5%
13.0%
9.7%

10.1%

9.1%
6.5% 7.1% 6.4%
4.6%

Any CRN

4.3%

CRN by Using Smaller Doses

Total

7.5% 8.0%

6.9%
5.4% 5.4%
3.7%

5.2%

4.8%

3.4%

CRN by Skipping Some Doses

Asthma-COPD Overlap

7.9%

Asthma Only

COPD Only

CRN by Failing to Get
Prescription

6.8% 6.8%

4.4%

CRN by Delaying to Get
Prescription

No-Asthma No-COPD

Note: Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in fee-for-service Part A and
Part B during the calendar
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4.0%

CHAPTER 4
4 Impact of Initial Maintenance Therapy Type on Medication Adherence Trajectories
among Older Adults with Asthma and COPD Overlap
4.1 Abstract
Objective: To examine the impact of initial maintenance therapy (IMT) type (inhaled
corticosteroids (ICS) vs. fixed dose combinations of ICS and long acting beta agonists
(ICS/LABA)) on trajectories of adherence among Asthma and Chronic Obstructive Pulmonary
Disease overlap (ACO) among older adults (> 65 years).
Methods: This study used a retrospective cohort of older adults with ACO using longitudinal
data from a 10% sample of Optum’s Deidentified Clinformatics ® Data Mart. We adopted
group-based trajectory modeling to identify medication adherence trajectories over 12 months.
Multinomial logistic regressions were used to evaluate the unadjusted and adjusted association of
IMT medication and adherence trajectory categories. All analyses accounted for treatment option
selection bias with inverse probability treatment weighting.
Results: Of 1,555 individuals, 73% of the sample used ICS/LABA for IMT. Four medication
adherence trajectories were observed regardless of regimen: 1) persistent high adherence
(12.0%); 2) progression to high adherence (20.8%); 3) progression to low adherence (10.5%) and
4) persistent low adherence (56.7%). Those who were initiated on ICS/LABA were less likely to
have “persistent low adherence” (Unadjusted Odds Ratio = 0.44, 95% Confidence Interval (CI)=
[0.29, 0.67]) as compared to those with ICS monotherapy when “persistent high adherence” was
used as the reference group. The relationship remained significant in adjusted regressions
(Adjusted Odds Ratio = 0.38, 95% CI = [0.24, 0.59]).
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Conclusions: Real-world evidence suggests that using ICS/LABA for IMT may decrease the
likelihood of “persistent” low adherence over time among older adults with ACO compared to
ICS monotherapy.
4.2 Introduction
Many adults have co-existing asthma and Chronic Obstructive Pulmonary Disease (COPD)
known as “Asthma-COPD overlap” (ACO)9. Treatment for ACO requires treating both the
underlying asthma and COPD by using maintenance therapy with inhaled medications. The joint
guidelines of Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive
Lung Disease (GOLD) recommend inhaled corticosteroids (ICS) with or without a long-acting
beta-agonist (LABA) for initial maintenance therapy (IMT) of individuals with ACO7,3.
Compared to ICS monotherapy, use of ICS/LABA for IMT of ACO has some advantages.
First, ICS/LABA can reduce both the inflammatory nature of asthma and the obstructive nature
of COPD 19. Second, prior studies indicate using ICS/LABA may improve medication adherence
compared to ICS. Although the association of using ICS/LABA and adherence to IMT has not
been directly studied among patients with ACO, these findings have been noted among patients
with asthma48,118–121. One possible reason is that the use of LABA in fixed-dose combination
with ICS has demonstrated benefit in reducing symptoms and exacerbations quickly compared to
ICS monotherapy which may increase the medication value to the patient122,123. Finally, one
observational study reported that ICS/LABA reduced the risk of myocardial infarction,
hospitalization, and death among patients with ACO, as compared to ICS monotherapy47.
To date, no study has evaluated adherence to IMT or the effect of IMT type on medication
adherence among older adults with ACO. However, this is a crucial topic to better understand
because older adults are the most vulnerable group of individuals to experience poor adherence
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and subsequent negative outcomes. Older adults (age > 70 years) often have higher prevalence of
poor medication adherence, compared to younger adults (age < 50 years), due to regimen
complexity, polypharmacy, prescription costs, and multiple comorbidities 124,125. For example,
prior studies have suggested that 70% of COPD patients 30 and nearly 50% of adults with
asthma27 have poor adherence to IMT, suggesting that such patterns may also be present in older
adults with ACO. Poor medication adherence can amplify the negative health effects of older
adults with ACO. Among patients with asthma or COPD, poor adherence to maintenance
therapy is associated with increased risk of adverse events such as hospitalization, disease
burden, and mortality. 126–128 Therefore, older individuals with ACO may also experience these
negative consequences, perhaps to an even greater degree.
It is important to analyze medication adherence over time because static adherence metrics
(e.g. proportion of days covered (PDC) or medication possession ratio (MPR)) average
adherence over time and ignore “within” individuals’ differences in adherence over time.129 For
example, an individual who uses medications for the first six months and discontinues for the
following six months will have the same PDC as an individual who uses the prescription every
other month. As medication adherence is known to vary over time among adults with chronic
lung diseases31, examination of adherence trajectories over time is important. Such information
can precisely locate the time point at which adherence changes. Furthermore, adherence
trajectories can guide development of customized intervention efforts at the right time130.
Therefore, the current study used group-based trajectory modeling (GBTM) of adherence
to IMT over time and analyzed the association of IMT type to trajectory membership among
older adults using claims data from Optum Clinformatics ® DataMart. Although, GBTM method
has been previously used for studying patterns of medication adherence to IMT among patients
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with asthma25, this study is the first application of the GBTM approach for examining
individuals with ACO.
4.3 Methods
Data Source
This study used health insurance claims from a 10% sample of Optum Clinformatics ®
DataMart from 1/1/2007 through 6/30/2017. This database contains information on prescription
claims [e.g. NDC codes, generic drug names, prescription fill dates, days supply, and costs of
medications], inpatient and outpatient medical claims [e.g. International Classification of
Diseases (ICD) 9th and 10th revision diagnoses, date of service, and costs of services], and
eligibility information [e.g. sex, date of birth, plan type, and insurance type].
Study Design
We used a longitudinal retrospective cohort design with a 24-month observation period
(12-month baseline and 12-month follow-up periods). We anchored the baseline period and the
follow-up period to the index date (i.e. first observed ICS or ICS/LABA fill date between
10/1/2008 to 9/30/2016). Baseline consisted of 12 months before the index date. The baseline
period was used to identify ACO and other characteristics. In the 12-months follow up period,
we measured medication adherence every month. Thus, each person had 12 observations (T1 to
T12).
Study Cohort: Older Adults with ACO
Only individuals with ACO diagnosis were included in this study. The first step involved
the identification of patients with either asthma or COPD during the baseline period. We
identified asthma or COPD by using the International Classification of Diseases, Clinical
Modification (ICD) 9 or ICD10 codes (Appendix 7.2). These diagnosis codes were derived from
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published research73,74. Individuals were required to have at least one inpatient visit or two
outpatient visits (at least 14 days apart) with either asthma or COPD codes. Individuals with both
asthma and COPD diagnoses during the baseline were identified as indivduals with ACO.
The study cohort included only older (age > 65 years) Medicare advantage beneficiaries
who initiated maintenance therapy with ICS monotherapy or ICS/LABA from 10/1/2008 to
9/30/2016. These patients were required to have continuous enrollment in both the baseline and
follow-up periods. We excluded individuals who used any other maintenance therapy (i.e. ICS,
LABA, long acting muscarinic antagonist (LAMA), and their combination forms) during the 12month pre-index period (Appendix 7.9).
Measures
Dependent Variables: Medication Adherence and Medication Adherence Trajectory Categories
derived from GBTM
We measured adherence to ICS or ICS/LABA for every 30-days during the follow-up
period. We created binary variables (yes/no) for each month based on the days supply for each
month after the index date25. These 12 dichotomized monthly indicators were used in a GBTM.
As described below, the GBTM model yielded four medication adherence patterns: (1) persistent
high adherence; (2) progression to high adherence; (3) progression to low adherence; and (4)
persistent low adherence. These categories were used as the dependent variable to analyze the
association of IMT type to medication adherence.
Key Independent Variable: Type of IMT (ICS and ICS/LABA)
Two usual treatment options for IMT were ICS monotherapy and fixed-dose combination
of ICS/LABA. National drug codes were used to identify these medications. To ensure that
individuals used ICS or ICS/LABA as IMT, we defined a look-back period of 365 days and only
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individuals who did not have any ICS, ICS/LABA, LABA, or LAMA use were considered as
initiating maintenance therapy.
Other Independent Variables
Selection of covariates was guided by the Anderson Health behavior model50. Per the
framework, adherence to IMT may be affected by: (1) pre-disposing variables (sex
[male/female], age); (2) enabling factors (insurance plan [health maintenance organization
(HMO)/Non-HMO], annual out-of-pocket prescription costs); (3) need factors (dementia
[yes/no], depression [yes/no], anxiety [yes/no], diabetes [yes/no], heart diseases (the presence of
at least one of the following: chronic heart failure, coronary artery disease, or arrhythmia)
[yes/no], hypertension [yes/no], the number of other chronic conditions (cancer, arthritis,
hyperlipidemia, hepatitis, HIV, osteoporosis, chronic kidney disease, stroke), the number of short
acting beta agonists (SABA), the number of courses of oral corticosteroids or antibiotics,
polypharmacy [concomitant use of five or more classes of medications within a 90 day period
before the index date]); (4) personal health practices (obesity diagnosis [yes/no] and tobacco use
diagnosis [yes/no]; (5) external factors (region [Northeast/Midwest/ South/West]).
Statistical Analyses
Accounting for Selection Bias of Treatment:
We observed significant differences in baseline characteristics by IMT type.
Specifically, individuals using ICS/LABA were more likely to be male, enrolled in non-HMO
plans, to be prescribed a SABA, more likely to live in the Southern region of the US, more likely
to have clinically recorded tobacco use, and less likely to have diagnosed anxiety, as compared
to ICS monotherapy. To control for this observed selection bias, we derived inverse probability
of treatment weights (IPTW). IPTWs were estimated from a logistic regression in which IMT
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type (ICS vs ICS/LABA) was the dependent variable. The covariates included sex, age, being
enrolled in an HMO plan, out-of-pocket prescription costs, presence of diabetes, anxiety,
depression or heart diseases, number of SABA, tobacco use diagnosis, the number of courses of
antibiotics, and region of residency. IPTWs were then used in the GBTM of medication
adherence. Once the medication adherence patterns were identified, we compared the unadjusted
and adjusted associations of IMT type to the trajectory groups using the IPTW-adjusted
multinomial logistic regressions.
Identification of Medication Adherence Trajectory Groups:
We identified clusters of patients with similar adherence patterns using the GBTM
method. GBTM uses the maximum likelihood estimation to identify changes in medication
adherence patterns over time. 131,132 GBTM uses the data to empirically group individuals. Under
this method, patterns of adherence are identified based on linear and non-linear specifications
and the probabilities of each individual belonging to these trajectories are calculated. Individuals
are assigned to the group for which they have the highest probability. We used different
specifications to identify these groups by using either cubic, quadratic, or quartic terms133,134.
Evaluating Medication Adherence by Using Generalized Estimating equations:
In addition to GBTM, we also used unadjusted and adjusted generalized estimating
equations (GEE) to evaluate the association of IMT type to medication adherence over time. We
used population-averaged GEE for repeated measures. Results from the GEE analyses are
summarized in Appendix 7.10. All data management and analyses were conducted with SAS 9.4
(SAS Institute Inc., Cary, NC) and Stata 14 (Stata Corp LLC, College Station, TX) was used for
GBTM and GEE modeling.

56

4.4 Results
Sample Characteristics Baseline Characteristics
In our study cohort of older adults with ACO and initiated on ICS or ICS/SABA as IMT
(N = 1,554), the majority were female (66.6%); mean age was 75.2 + 6.1 years. The majority of
individuals were enrolled in an HMO plan (64.9%). The baseline characteristics of our study
cohort is provided in Appendix 7.11. An overwhelming majority (73.2%) used ICS/LABA and
26.8% used ICS for IMT.
IPTW-adjusted Baseline Characteristics by IMT Type
The unweighted numbers and IPTW-adjusted weighted percentages baseline
characteristics by IMT type are displayed in Table 1. As can be seen in Table 1, there were no
statistically significant differences in baseline characteristics between the two groups after IPTW
adjustments.
Identification of Medication Adherence Trajectories with GBTM
We initially specified eight groups with quadratic and higher-order polynomial
specifications. After a preliminary examination of the results, we finalized trajectories to four
groups based on the following criteria: 1) the Bayesian information criterion (BIC); 2)
significant p-values (<.05) for the highest-order polynomial parameter; 3) at least 5% of the
population assigned to each trajectory group; 4) no polynomial overfitting; 5) narrow confidence
intervals; and 6) clinically meaningful grouping131,135–137. The final trajectory model passed all
Nagin's diagnostic criteria of the “average of posterior probabilities (PP) >0.7” and the “odds of
correct classification (OCC) >0.5” for all groups 131,136.
As shown in Figure 1, we identified four different adherence trajectories. These
trajectories can be described as: (1) persistent low adherence (56.7%); (2) persistent high
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adherence (12.0%), 3) progression to low adherence (10.5%); and (4) progression to high
adherence (20.8%).
Unadjusted and Adjusted Associations of IMT type to Adherence Trajectory Groups
The four adherence trajectories were significantly different in terms of IMT type (Table
2) with a higher percentage of individuals who used ICS/LABA having “persistent high
adherence”, compared to those prescribed ICS monotherapy (82.9% vs. 68.1). Unadjusted odds
ratios (UOR), adjusted odds ratios (AOR), and 95% Confidence intervals (CI) from the
multinomial logistic regressions on medication adherence categories are summarized in Table 3.
In the unadjusted multinomial logistic regression models, those who were initiated on
ICS/LABA were 56% less likely to have “persistent low adherence” (UOR = 0.44, 95% CI [0.29,
0.67]), compared to those with ICS monotherapy when “persistent high adherence” was used as
the reference group for the dependent variable. The relationship remained significant in adjusted
regressions that controlled for only predisposing factors (AOR = 0.44, 95% CI = [0.29, 0.66])
and remained significant in all subsequent models. In the fully adjusted model, those with
ICS/LABA as IMT were less likely to have “persistent low adherence” (AOR= 0.37, 95% CI =
[0.24, 0.59]).
4.5 Discussion
This study is the first study to report longitudinal patterns of adherence to IMT among
older adults with ACO seeking care in real-world practices and who were initiated on ICS or
ICS/LABA for maintenance therapy by using a GBTM approach. In our study cohort of older
adults with ACO, ICS/LABA use was very common, with three in four older adults using
combination therapy. In a study conducted on adults (>18 years) using 2008 and 2011 Truven
Health Analytics MarketScan Commercial and Medicare Supplemental databases approximately
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75% of adults with ACO and on maintenance therapy were prescribed ICS/LABA 74. The
differences in the prevalence rate of ICS/LABA can be due to differences in study population,
time period, and insurance coverage.
We identified four distinct patterns of medication adherence: 1) persistent low adherence;
2) persistent high adherence; 3) progression to low adherence and 4) progression to high
adherence. Overall, the majority of older adults (57%) had persistent poor adherence and only
11% had “persistent high adherence.” As there are no published studies on medication adherence
trajectories over time among older adults with ACO, we compared our results to studies that
focused on adults with asthma or COPD. A recent study conducted in Australia reported that the
“persistent low adherence” trajectory to IMT was observed among 58% of individuals between
12 and 45 years old. Studies that use PDC for measuring medication adherence also reported the
high prevalence of medication non-adherence (<80% PDC) among patients with asthma or
COPD. For example, a systematic review of 39 clinical trials reported that only 47% to 57% of
individuals with asthma were adherent to maintenance therapy27. Moreover, in a retrospective
cohort study on Medicare beneficiaries with COPD, the average monthly adherence to IMT was
plateaued at 35% by the seventh month31. Our study’s findings demonstrating that the majority
of older adults with ACO had persistent low adherence is concerning. This finding suggests that
there is a significant room for improvement in adherence to achieve better disease management,
improved patient safety, and reduced exposure to unnecessary treatment intensification.
The results of this study confirmed that the adherence to IMT varies over time. For
example, one third of patients changed their adherence behavior after six months of starting IMT.
This may indicate a heightened surveillance of adults who were initiated on IMT, and there may
be a limited “window of opportunity” to deliver evidence-based interventions that improve
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adherence. Although there are many types of interventions to improve medication adherence
among individuals with asthma or COPD, motivational interviewing138, coaching and patient
education 139, shared decision-making140, and simplification of regimen141 have been proven to
improve adherence. Our study findings suggest that these interventions may need to be delivered
at the right time to improve medication adherence.
Our study findings also suggest that the type of therapy (type of IMT) may be an
important modifiable factor for reducing the risk of consistent low-adherence. In our study,
older adults who were initiated on ICS/LABA were less likely to have “persistent low
adherence”. Previous studies among patients with asthma also support this finding. A clinical
trial conducted by Perrin et al. reported that adherence to ICS/LABA was marginally higher, as
compared to ICS monotherapy142. Similarly, four observational studies among patient with
asthma concluded that that use of ICS/LABA is likely to improve adherence to IMT or
maintenance therapy compared with ICS 48,118–121. As stated in the introduction ICS/LABA
confers many advantages. Although many patients perceive that inhalers are effective in
relieving symptoms, this perceived efficacy of ICS/LABA may be higher. This higher perceived
efficacy can be due to a faster improvement of symptoms by using ICS/LABA. A previous
clinical trial among patients with asthma has reported that ICS/LABA resulted in a faster
improvement in asthma symptoms compared to ICS monotherapy for IMT143. While simplifying
a medication regimen is optimal for improved adherence, prescribers do not need to order two
inhalers to achieve dual therapy; ICS/LABA are available in combination as one inhaler. Future
randomized clinical trials are needed to investigate the differences in improvement of symptoms
between ICS/LABA and ICS for IMT of ACO. Our study findings also suggest that therapy-
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related factor (type of IMT) may be an important modifiable factor in reducing the risk of
consistent low-adherence.
4.6 Limitations
This study has some limitations. One limitation is the use of medication fills data for
assessing adherence. In fact, adherence based on medication fills data assumes that filled
medications are taken and used properly by patients. This assumption can result in
overestimating adherence. As this study used retrospective cohort design using claims data, it has
the inherent limitations of the observational study (under coding of diagnosis, lack of clinical
markers of disease severity, and lack of information on behavioral variables). Other factors that
may impact adherence to IMT (e.g. patient-physician communication, severity of symptoms, fear
of side effects, and family support) were not adjusted, and this may change the impact of IMT
type on adherence behavior.
4.7 Conclusion
Among older adults with ACO seeking care in real-world settings, we identified potential
concern with high rates of non-adherence based on fill rates. Our study findings suggest that
using ICS/LABA for IMT may reduce the risk of “persistent low adherence” over time among
older adults with ACO. Future studies need to target older with consistently low adherence to
maintenance therapy to explore drug-related and non-drug-related factors that are barriers or
facilitators to adherence patterns over time.
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ALL
Sex

Table 4.1
Characteristics of Older Adults with Asthma-COPD Overlap
by Initial Maintenance Therapy Options
Inverse Probability Treatment Weighting
Optum Clinformatics 10% Sample, 2007-2017
ICS/LABA
ICS
N/ Mean
Wt %
N
1137
73.2
417

Wt %
26.8

Sig

Female
757
66.6
276
66.4
Male
380
33.4
140
33.6
Age (Mean, SD)
75.01
6.06
75.75
6.27
Insurance Plan
HMO
739
64.9
270
64.9
Non- HMO
399
35.1
146
35.1
Out-of-pocket Payments for
Prescription Drugs (Mean, SD)
533.22
739.23
552.41
750.56
Depression
Yes
145
12.8
52
12.4
No
992
87.2
365
87.6
Anxiety
Yes
120
10.5
44
10.5
No
1018
89.5
373
89.5
Diabetes
Yes
410
36.0
165
39.6
No
727
64.0
252
60.4
Hypertension
Yes
802
70.5
304
72.9
No
335
29.5
113
27.1
Heart Diseases
Yes
481
42.3
171
41.1
No
656
57.7
245
58.9
# Other Chronic Conditions
0
218
19.2
70
16.7
1-2
708
62.2
268
64.4
3-4
211
18.6
79
18.9
# SABA (Mean, SD)
1.75
2.77
1.78
2.73
Polypharmacy
Yes
794
69.8
303
72.7
No
343
30.2
114
27.3
Obesity Diagnosis
Yes
198
17.4
66
15.9
No
939
82.6
350
84.1
Tobacco Use Diagnosis
Yes
143
12.6
50
11.9
No
994
87.4
367
88.1
Region
Northeast
125
11.0
46
10.9
Midwest
200
17.6
74
17.7
South
442
38.9
161
38.8
West
369
32.5
136
32.6
Note: Based on 1,556 older adults aged 65 years or older with ACO diagnosis, initiated on maintenance therapy (either
inhaled corticosteroid only or fixed dose combination of inhaled corticosteroids and-long-acting beta agonist) and
continuously enrolled during the observation period.
Abbreviations: ACO: Asthma COPD Overlap; HMO: Health Maintenance Organization; SABA: Short-Acting
Beta Agonist; SD: Standard deviation; Sig: Significance; Wt: Weight; #: Number
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Table 4.2
Characteristics of Older Adults with Asthma-COPD Overlap
By Medication Adherence Trajectories
Initiated on Maintenance Therapy
Optum Clinformatics 10% Sample, 2007-2017
Persistent Low
Progression to
Progression to
Persistent High
Adherence
Low Adherence
High Adherence
Adherence
N
Wt %
N
Wt %
N
Wt %
N
Wt %
891
57.3
322
20.7
166
10.7
177
11.4

Sig

ALL
IMT Type
***
ICS/LABA
607
68.1
257
79.8
128
77.1
145
82.9
ICS
284
31.9
65
20.2
38
22.9
30
17.1
Sex
Female
596
66.9
207
64.3
115
69.3
117
66.9
Male
295
33.1
115
35.7
51
30.7
58
33.1
Age (Mean, SD)
75.1
6.1
75.1
6.0
75.2
6.2
75.9
6.2
***
Insurance Plan
HMO
579
65.0
211
65.5
112
67.5
107
61.1
Non- HMO
312
35.0
111
34.5
54
32.5
68
38.9
OOP Prescription Costs
5.3
7.0
5.9
9.1
6.1
7.7
3.9
4.8
*
in hundreds (Mean (SD)
Depression
Yes
126
14.1
34
10.6
18
10.8
23
13.1
No
765
85.9
288
89.4
148
89.2
152
86.9
Diabetes
**
Yes
354
39.7
116
36.0
47
28.3
52
29.7
No
537
60.3
206
64.0
119
71.7
123
70.3
Heart Diseases
+
Yes
398
44.7
130
40.4
58
34.9
66
37.7
No
493
55.3
192
59.6
108
65.1
109
62.3
# Other Chronic
Conditions
0
163
18.3
58
18.0
30
18.1
35
20.0
1-2
556
62.4
211
65.5
107
64.5
104
59.4
3 and more
172
19.3
53
16.4
29
17.5
36
20.5
# SABA
***
0
342
38.4
115
35.7
64
38.6
51
29.1
1-3
455
51.1
151
46.9
72
43.4
81
46.3
4-6
62
7.0
34
10.6
17
10.2
25
14.3
>7
32
3.6
22
6.8
13
7.8
18
10.3
> 2 Courses of Antibiotics
*
Yes
469
52.6
148
46.0
78
47.0
72
41.1
No
422
47.4
174
54.0
88
53.0
103
58.9
Polypharmacy
Yes
628
70.5
225
69.9
120
72.3
124
70.9
No
263
29.5
97
30.1
46
27.7
51
29.1
Obesity Diagnosis
Yes
158
17.7
59
18.3
23
13.9
20
11.4
No
733
82.3
263
81.7
143
86.1
155
88.6
Region
Northeast
100
11.2
32
9.9
19
11.4
21
12.0
Midwest
133
14.9
71
22.0
31
18.7
38
21.7
South
363
40.7
117
36.3
67
40.4
58
33.1
West
295
33.1
102
31.7
49
29.5
58
33.1
Note: Based on 1,556 older adults aged 65 years or older with Asthma Chronic Obstructive Pulmonary Disease Overlap, initiated
on maintenance therapy (either inhaled corticosteroid only or fixed dose combination of inhaled corticosteroids and-long-acting
beta agonist) and continuously enrolled during the observation period.
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Abbreviations: ACO: Asthma COPD Overlap; HMO: Health Maintenance Organization; ICS: Inhaled Corticosteroid;
ICS/LABA: Fixed dose combination of inhaled corticosteroid-and-long-acting beta agonist; IMT: Initial Maintenance Therapy; N:
Number; OOP: Out of Pocket; SABA: Short-Acting Beta Agonist; SD: Standard deviation; Sig: Significance; Wt: Weight; #:
Number ***p<.001,**.001<p<.01,*.01<p<.005,+ .05< p<.1
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Table 4.3
Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from
Multinomial Logistic Regressions on Medication Adherence Trajectory Groups
with Persistent High Adherence as Reference Group
Inverse Probability Treatment Weighting
among Older Medicare Beneficiaries with ACO and Initiated on Maintenance Therapy
Optum Clinformatics 10% Sample, 2007-2017
Persistent Low Adherence
Progression to Low
Progression to High
Adherence
Adherence
UOR
95% CI
Sig
UOR
95% CI
Sig
UOR
95% CI
Sig
Model 1: Unadjusted
IMT Type (Ref: ICS)
ICS/LABA

0.44
AOR

[ 0.29 , 0.67]
95% CI

***
Sig

0.79
AOR

[ 0.49, 1.28]
95% CI

Sig

0.69
AOR

Model 2: Adjusted by Predisposing Factors
IMT Type (Ref: ICS)
ICS/LABA
0.44
[ 0.29 , 0.66]
***
0.79
[ 0.49, 1.27]
0.69
Model 3: Adjusted by Predisposing and Enabling Factors
IMT Type (Ref: ICS)
ICS/LABA
0.44
[ 0.29 , 0.67]
***
0.79
[ 0.49, 1.27]
0.69
Model 4: Adjusted by Predisposing, Enabling, Personal Health Practice and External Factors
IMT Type Status (Ref: ICS)
ICS/LABA
0.43
[ 0.28 , 0.66]
***
0.78
[ 0.48, 1.26]
0.67
Model 5: Adjusted by Predisposing, Enabling, Personal Health Practice, External , and Need Factors
IMT Type (Ref: ICS)
ICS/LABA
0.37
[ 0.24 , 0.59]
***
0.70
[ 0.42, 1.18]
0.59

[ 0.40 , 1.18]
95% CI

Sig

[ 0.40 , 1.18]

[ 0.40 , 1.18]

[ 0.39 , 1.16]

[ 0.33 , 1.04]

Note: Based on 1,556 older adults aged 65 years or older with Asthma Chronic Obstructive Pulmonary Disease overlap, initiated on
maintenance therapy (either inhaled corticosteroid only or fixed dose combination of inhaled corticosteroids and-long-acting beta
agonist) and continuously enrolled during the observation period.
Pre-disposing factors were sex, and age. Enabling factors consisted of insurance plan type, annual out-of-pocket payments for
prescription drugs. Personal health practices were: Obesity diagnosis and tobacco use recorded in claims. External environmental
factors included region of residency. Need factors were: dementia, depression, anxiety, diabetes, heart diseases, hypertension, the
number of other chronic conditions, the number of SABA, the number of courses of oral corticosteroids, the number of courses of
antibiotics, and polypharmacy.
Abbreviations: ACO: Asthma Chronic Obstructive Pulmonary Disease Overlap; ICS: Inhaled Corticosteroid; ICS/LABA: Fixed dose
combination of inhaled corticosteroid-and-long-acting beta agonist; ref: reference group; SABA: Short-Acting Beta Agonist; Sig:
Significance
***p<.001
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Figure 4.1
Trajectories of Adherence to Initial Maintenance Therapy
Among Older (> 65 years old) Adults with Asthma-COPD Overlap
Optum Clinformatics 10% Sample, 2007-2017
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CHAPTER 5
5 Summary and Conclusion
5.1 Summary of Findings and Discussion
Prevalence of ACO
In our study, the overall prevalence of ACO was 1.5% among community dwelling
Medicare beneficiaries. Although no study has reported the specific prevalence of ACO among
community dwelling Medicare beneficiaries, this estimate is less than 3.8% which was
previously reported by Kumbhare et al for (65-85 years old) older adults in the United States14.
Possible explanations of this difference are methods of identification and time period. While this
study used fee-for-service Medicare claims for identification of ACO during a calendar year
Kumbhare et. Al. used “ever diagnosed” using self-reports. Thus, we may have captured only
older adults who had received healthcare services for asthma and COPD.
Excess Economic Burden of ACO in Terms of Total Health Care Expenditures and ThirdParty Payers’ Expenditures
In terms of projected total healthcare expenditures, nearly two billion dollars (2013USD)
were spent on healthcare (weighted number of ACO adults in 2013= 42,984 multiplied by the
average per-capita cost $45,532) of older community-dwelling adults with ACO. In terms of the
excess economic burden (i.e. total health care expenditures and third-party payers’ expenditures)
individuals with ACO had almost four, two, and 1.5 times higher expenditures compared to
individuals with NANC, asthma only, and COPD only. Even after controlling for multiple
determinants of expenditures, the presence of ACO was associated with significantly higher
expenditures in comparison with individuals with NANC, asthma only, and COPD only –
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consistent with published studies that compared per-capita expenditures of individuals with ACO
to those with asthma only17 or those with COPD only18.
The excess expenditures associated with ACO is not surprising because studies have
documented increasing expenditures with an increasing number of chronic conditions80.
Furthermore, our finding that ACO patients had higher economic burden compared those with
asthma only or COPD only suggest that ACO adults may have higher rates healthcare utilization
including hospitalization and emergency department/urgent care visits, which contribute to the
higher expenditures. In a cohort of 17,088 COPD patients in Taiwan, ACO patients experienced
almost twice as many acute respiratory events (e.g. acute respiratory failure, pneumonia, and
acute exacerbation) than did the rest of the COPD cohort12.
Excess Economic Burden of ACO for Patients and Their Families: Out-of-Pocket
Healthcare Expenditures
In this study, those with ACO had higher odds of high OOP spending burden compared
to all other groups in both unadjusted and adjusted models. This high burden could be due to
cost-sharing of Medicare-covered services, including prescription drugs and payments for noncovered services by Medicare. OOP burden may be particularly high among individuals with
ACO because of high cost-sharing of inhaler medications. Based on data from nationwide Part D
plans, it has been estimated that mean OOP expenditures were $30–$105 per inhaler in 201564.
This means that a typical older Medicare beneficiary with ACO who is prescribed 2-3 inhalers
per month has annual OOP expenditures of at least $1,622–$2,81l for his/her inhalers64.
Individuals with ACO may have greater need for some of the services not covered by
Medicare (example: dental, hearing, and vision) compared to NANC as they are higher risk of
these conditions. For example, individuals with ACO have significantly higher odds (AOR =
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1.82, 95% CI = [1.59, 2.08], P<0.001) of removing all teeth compared to NANC81, suggesting
greater spending on oral healthcare by patients. It has also been reported that COPD patients are
vulnerable to low-value care82, which may increase OOP spending of families and patients
through cost-sharing. Medicare reform proposals that focus on value-based healthcare that
balance the value of health services to the OOP spending burden of patients may reduce the
excess economic burden of patients.
Contribution of Differences in Patient Characteristics to the Excess Economic Burden of
ACO
The current study used linear and non-linear decomposition analyses to examine the
drivers of the excess economic burden of chronic respiratory conditions, one of the top four
conditions of public health concern designated by the World Health Organization (WHO) 83. The
other three conditions are cardiovascular disease, diabetes, and cancer. It has to be noted that
older adults with chronic respiratory conditions also have higher rates of CVD, diabetes, and
cancer. A population survey among (>18 years) adults in the US also found that the adjusted
odds of six chronic conditions (e.g. cardiovascular diseases, diabetes, and depression) is higher
in ACO compared to asthma only and COPD only 14. In our study, 91% of ACO patients had
more than two other chronic conditions which was higher than asthma only (89%), COPD only
(87%) and NANC (76%) groups. Our decomposition analysis suggested that patient-level
characteristics such as higher number of co-existing chronic conditions and related
characteristics (i.e., higher number of unique medications, and higher levels of fragmented care)
were the leading drivers of the excess economic burden among ACO patients. For example,
receiving care from several different providers often results in gaps in communication between
providers which can lead to suboptimal care and polypharmacy75,84. Prior studies suggest that
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more fragmented care is associated with more diagnostic tests, more low-value care, and lower
patient satisfaction85–87. Previous studies further suggest the associations of fragmented care and
higher number of emergency department (ED) visits, higher hospitalizations, and higher
expenditures77,88.
Cost-Related Medication Non-Adherence and ACO
One in six older Medicare beneficiaries with ACO reported any CRN between 2006 and
2013. The most prevalent form of CRN was “failing to fill prescription,” which was almost twice
as high among Medicare beneficiaries with ACO compare to those with no-asthma and noCOPD. Older adults with ACO were more likely to report any CRN compared to older adults
with no-asthma no-COPD; while not directly studied, this likely has significant later-in-life
morbidity and mortality consequences76,98. This is not surprising because older adults with ACO
compared to those with neither asthma nor COPD had higher OOP burden, and high OOP burden
was significantly associated with CRN. The high OOP burden among adults with ACO can be
explained by the high cost of brand-name inhaler therapies and the high medication burden per
individualized regimen to adequately manage ACO (often two to three inhaler therapies).
Role of Number of Medication in High Risk of CRN among Patients with ACO
In our study, increased risk of any CRN among ACO individuals compared to those with
no-asthma no-COPD is apparent by adjusting all factors without number of unique medications.
However, the inclusion of number of unique medications attenuated this association, suggesting
that number of medications may be a key link between ACO and CRN. Notably, the mean
number of unique medications is approximately 16 among individuals with ACO which is
significantly higher compared to individuals with asthma-only (~13), COPD-only (~12.5) and
no-asthma no-COPD (~7). Individuals with ACO have a higher number of unique medications
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due to two following reasons: (1) individuals with ACO may need to use a higher number of
respiratory medications to adequately control respiratory symptoms. The Latin American Project
for the Investigation of Obstructive Lung Disease (PLATINO) study found that 49% of
individuals with ACO used respiratory medications significantly higher than individuals with
asthma-only (38%) or COPD-only (20%)13; (2) ACO individuals may need to use a greater
number of non-respiratory medications due to higher risk of comorbid medical conditions. In our
study, 43% of ACO individuals had 4-6 other chronic conditions, while this number was lower
among individuals with asthma-only (33%), COPD-only (36%), and no-asthma no-COPD
(23%). A population survey in the US similarly found that 90% of individuals with ACO had at
least one other co-existing condition (compared with 71% in asthma-only and 84% in COPDonly)14.
Trajectories of Adherence to IMT among Patients with ACO
We identified four distinct patterns of medication adherence: (1) persistent low
adherence; (2) persistent high adherence; (3) progression to low adherence; (4) and progression
to high adherence. The majority of older adults (57%) had persistent poor adherence and only
11% had “persistent high adherence.” As there are no published studies on medication adherence
trajectories over time among older adults with ACO, we compare our results to studies that
focused on adults with asthma or COPD. Our study findings are consistent with published
studies that have reported low adherence to maintenance therapy among individuals with either
asthma or COPD. A recent study conducted in Australia reported that the “persistent low
adherence” trajectory to IMT was observed among 58% of individuals with asthma who were
between 12 and 45 years old 25. Studies that use PDC for measuring medication adherence also
reported the high prevalence of medication non-adherence (<80% PDC) among patients with
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asthma or COPD. For example, a systematic review of 39 clinical trials reported that only 47% to
57% of individuals with asthma were adherent to maintenance therapy27. Similarly, a study of
244 patients with COPD reported that adherence to maintenance therapy with ICS/LABA was
less than 23%28. Poor adherence to maintenance therapy was reported particularly higher among
the elderly population. In a retrospective cohort study on Medicare beneficiaries with COPD, the
average monthly adherence to IMT was plateaued at 0.35 by the seventh month31.
Type of IMT and Trajectories of Adherence among Patients with ACO
In our study cohort of older adults with ACO, 26.8% were initiated on ICS monotherapy
and 73.2% were initiated on ICS/LABA. This means that the percentage of older adults with
ACO who used ICS/LABA for IMT is three times higher than those who used ICS for IMT.
An important finding of this study is that older adults who were initiated on ICS/LABA were less
likely to have “persistent low adherence”. Previous studies among patients with asthma also
support this finding. A clinical trial conducted by Perrin et al. reported that adherence to
ICS/LABA was higher as compared to ICS monotherapy142. Similarly, two other studies among
the patient with asthma concluded that that use of ICS/LABA is likely to improve adherence to
IMT compared with ICS 120,121. As stated in the Introduction, ICS/LABA confers many
advantages. Although many patients perceive that inhalers are effective in relieving the
symptom, this perceived efficacy of ICS/LABA may be higher. This higher perceived efficacy
can be due to a faster improvement of symptoms by using ICS/LABA. A previous clinical trial
among patients with asthma has reported that ICS/LABA resulted in a faster improvement in
asthma symptoms compared to ICS monotherapy for IMT143.
5.2 Implications and Suggestions for Future Research
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Our study findings highlight the need for a “holistic management” of older adults with chronic
respiratory conditions, specifically ACO, asthma, and COPD. Given many with chronic
respiratory conditions need to see multiple providers and use multiple medications concurrently
(example: inhaled corticosteroids, short- and long acting beta agonist) for managing their
respiratory symptoms110 and other medications to manage their chronic conditions), the risks of
fragmented care and drug-disease and drug-drug interactions are very high. These factors often
lead greater economic burden, as evidenced by our study. Although CMS began reimbursing
providers for providing coordinated care for those with multiple conditions in 201589, it remains
to be seen whether such fiscal incentives for care coordination have resulted in less fragmented
care and reduce healthcare expenditures. In this context, patients with chronic respiratory
conditions (ACO, and COPD) may need to be managed in patient-centered medical homes that
are “comprehensive, team-based, coordinated, accessible, and focused on quality and safety.” 90.
As documented in published literature, pharmacists can play an important role in medical homes
by counseling patients and/or caregivers, reviewing inhaler techniques, simplifying medication
regiments, and providing adherence assessments91–93. Such management may improve not only
outcomes, but also lower the economic burden of patients, payers, and health systems.
Our study’s findings highlight the need for developing guidelines for management of
multiple chronic conditions. Applying “single-disease focused” clinical practice guidelines can
result in adverse drug-drug and drug-disease interactions. A systematic review of
recommendations in 12 UK national clinical guidelines identified that potentially serious drugdrug interactions were common94. Adherence to guidelines for those with multiple chronic
conditions can also generate more low-value care and lead to higher healthcare expenditures the
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patient, payers, and the society95,96. Guidelines which focus on overlapping or larger scale care
would benefit patients with multiple comorbidities.
Reducing the number of medications may directly reduce the likelihood of CRN and
indirectly alleviate the high burden of OOP prescription cost among older adults with ACO. As
documented in published literature, clinicians and pharmacists can play an important role in
reducing the number of medications. For example, during annual wellness visits—now covered
by Medicare—a comprehensive review of medications can be performed and highlights
opportunities for prescription regimen optimization113. Providers can proactively participate in
deprescribing by: (1) discontinuing unnecessary therapy, (2) discontinuing duplicate therapies,
(3) combining therapies as appropriate (i.e. combination inhalers), and (4) replacing high-cost
therapies with more affordable options. In a survey of elderly Medicare beneficiaries, more than
30% of individuals reported they did not have the chance of talking with their provider about
their medications in the last 12 months114. Intensive, chronic care management can be optimized
through team-based care.
The results of this study suggest that the adherence to IMT varies over time. For example,
one third of patients changed their adherence behavior after 6 months of starting IMT. Hence,
there is a need to use appropriate adherence interventions at the right time. Different
interventions can be used to address poor adherence among patients with ACO. Interventions
such as motivational interviewing138, coaching and patient education 139, shared decisionmaking140, and simplification of regimen141 can be used for improving adherence among patients
with ACO as these interventions have successfully improved adherence among patients with
asthma or COPD. For designing personalized medication adherence intervention at the right
time, it is important to focus on underlying factors associated with poor adherence. Previous
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studies have suggested that patient-related, socioeconomic-related, health system–related,
condition-related, and therapy-related are contributed to poor adherence33. Among all these
factors, therapy related factors may be the least expensive modifiable factors among all.
Frequency, length, and complexity of regimen are some of the many therapy-related factors that
can impact adherence among patients with chronic pulmonary diseases 144. One important
therapy-related factor for IMT among individuals with ACO may be IMT type. Future
randomized clinical trials are needed to investigate the differences in improvement of symptoms
between ICS/LABA and ICS for IMT of ACO.
5.3 Strengths and Limitations
The strengths of this study are: (1) use of a nationally representative survey of elderly
Medicare beneficiaries linked to their fee-for-service claims data (Aims 1 & 2); (2) inclusion of a
comprehensive set of factors by using a strong framework for all aims; (3) examination of
leading drivers of the excess burden with advanced econometric techniques; (4) contribution to
knowledge gap by being the first study to examine the impact of medication type on adherence to
IMT (Aim 3); (5) use of real-world data from Medicare advantage database adults (Aim 3); (6)
adoption of longitudinal study design with adjustments for observed selection bias by using
IPTW (Aim 3) and; (7) and use of GBTM techniques (Aim 3) to identify adherence trajectories
over time.
Some limitations of the proposed research should be noted. Lack of information on the
severity of asthma and COPD is a limitation of this study. While some of the advanced methods
shed light on drivers of the excess economic burden and medication adherence over time, they
cannot explain reasons behind these issues. The study findings are not generalizable to all older
adults. Furthermore Aims 1 and 2 used cross sectional design and therefore cannot be used for
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establishing causal inference. Our measure of CRN was not specific to ACO medications. In
aim 3, we did not have information on sociodemographic characteristics which may affect
adherence and therefore we may have overestimated they effect of IMT type on adherence over
time. Furthermore, by using prescription fill data (Aim 3) and not actual use of medications to
define adherence, we may have not accurately measured medication adherence.
5.5 Conclusion
Overall among older adults, ACO was associated with excess economic burden (in terms
of total healthcare, third-party expenditures and OOP spending burden), even after adjusting with
a comprehensive list of variables. Post regression decomposition analyses revealed multiple
medications use and high levels of fragmented care were the leading drivers of the excess
economic burden. Older adults with ACO were also vulnerable for any CRN and its specific
forms. The high number of medications used among ACO individuals explained the association
of ACO to CRN. Furthermore, only one in 10 older adults with ACO had “persistent high
adherence” to IMT and nearly six in 10 older adults had “persistent low adherence” to IMT. Our
study’s findings suggest that using ICS/LABA for IMT may reduce the risk of “persistent low
adherence” over time among older adults with ACO. Individual, policy, and program
interventions that facilitate coordination of care may reduce the excess economic burden, and
CRN of older adults with chronic respiratory conditions, specifically ACO. Our study’s findings
highlight the need for heightened surveillance of ACO patients, policies and programs to reduce
the economic burden on patients, and holistic management of ACO patients within integrated
systems of healthcare delivery. Future prospective cohort studies are needed to confirm the study
findings as well as to identify reasons for non-adherence to inform intervention efforts.
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7. Appendices
Appendix 7.1
Attrition Table of Individuals Included in the Analysis Based on Inclusion and Exclusion Criteria

Number of individuals available in MCBS 2006-2013
90,551

Number of individuls at least 65 yeas old
74,689

Number of individuals with at least one full year enrollment
68,352

Number of individuls with community-dwelling status
41,819

Number of individuals who were alive during calendar year
39,446

Number of individuls without ghost id
39,295

Number of individuls who are enrolled in fee-for-service program

38,089
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Asthma

493.0
493.1
493.2
493.8
493.9

COPD

491.1
491.2
491.8
491.9
492
492.8
496

Appendix 7.2
Diagnosis Codes for Asthma and COPD
ICD-9-CM
J45.20
J45.21
J45.22
J45.30
J45.31
J45.32
J45.40
J45.41
J45.42
J45.50
J45.51
J45.52
J45.901
J45.902
J45.909
J45.990
J45.991
J45.998
J41.0
J41.1
J41.8
J42
J43.0
J43.1
J43.2
J43.8
J43.9
J44.0
J44.1
J44.9
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ICD-10-CM

Appendix 7.3
Characteristics of Elderly Community-Dwelling Fee-for-Service Medicare Beneficiaries
N
Wt. %
ALL
38,089
100.0
Sex
Female
21,469
56.2
Male
16,620
43.8
Age in Years
65-74
15,107
47.5
75-84
15,648
37.5
85 and above
7,334
15.1
Race/Ethnicity
White
31,529
82.6
Black
2,603
6.7
Latino
2,145
5.7
Other race
1,733
4.8
Marital Status
Married
19,775
54.2
Not married
18,298
45.7
Education
Less than high school
9,256
22.2
High school
13,751
35.5
Above high school
14,935
41.9
Poverty Status
Less than 200% FPL
18,382
45.6
At least 200% FPL
19,707
54.4
Prescription Coverage
Yes
23,700
61.6
No
14,389
38.4
Number of Unique Medications
0
1,714
5.1
1-4
9,266
25.3
5-7
9,008
23.5
8-11
8,897
22.8
12 and more
9,204
23.4
Number of Other Chronic
Conditions
0-1
7,845
22.3
2-3
20,286
53.0
4-6
9,949
24.6
Calendar Year
2006
5,776
13.2
2007
5,382
12.3
2008
4,965
11.7
2009
4,341
11.5
2010
4,077
11.5
2011
4,634
13.4
2012
4,602
13.2
2013
4,312
13.3
Note: Based on 38,089 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries continuously enrolled in
fee-for-service Part A and Part B during the calendar year, alive during the calendar year.
FPL: federal poverty level; N: unweighted number; Wt: weighted.
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Appendix 7.4.
Mean Annual Adjusted and Unadjusted Expenditure
Among Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
No-Asthma
No-COPD
Unadjusted
Costs

Unadjusted
Costs

Mean $
(SD)

Mean $
(SD)

Asthma COPD Overlap
Unadjusted
Incremental
Costs (ref:
NANC)
Mean $ Sig
(95% CI)

Adjusted
Incremental
Costs (ref:
NANC)
Mean $ Sig
(95% CI)

Asthma Only
Unadjusted
Costs

Mean $ (SD)

Inpatient
Costs
Outpatients
Costs
Prescription
Costs
Other Costs

Unadjusted
Incremental
Costs (ref:
NANC)
Mean $ Sig
(95% CI)

COPD Only
Adjusted
Incremental
Costs (ref:
NANC)
Mean $ Sig
(95% CI)

Unadjusted
Costs

Mean $ (SD)

Unadjusted
Incremental
Costs (ref:
NANC)
Mean $ Sig
(95% CI)

Adjusted
Incremental
Costs (ref:
NANC)
Mean $ Sig
(95% CI)

2,445
1,5691
3,284***
3,263***
5,068
3,184***
3,137***
9,643
3,852***
3,743***
(60)
(1203)
(3,196- 3,372)
(3,162- 3,364)
(548)
(3,097- 3,270)
(3,040- 3,233)
(397)
(3,758- 3,946)
(3,638- 3,848)
1,686
4,177
1,640***
2,102***
2,946
1,638***
2,103***
3,087
1,742***
2,183***
(50)
(470)
(1,596- 1,685)
(2,022- 2,181)
(248)
(1,594- 1,681)
(2,024- 2,187)
(142)
(1,697- 1,787)
(2,105- 2,261)
2,766
6,749
3,027***
4,163***
5,436
3,034***
4,157***
5,180
3,095***
4,461***
(45)
(307)
(2,988- 3,065)
(4,059- 4,266)
(485)
(2,996- 3,073)
(4,055- 4,260)
(127)
(3,057- 3,133)
(4,354- 4,568)
5,846
18,916
8,818***
6,261***
10,054
8,907***
6,266***
12,243
9773***
6949***
(111)
(1680)
(8,679- 8,958)
(6116- 6407)
(759)
(8,768- 9,046)
(6,121- 6,411)
(389)
(9,621- 9,926)
(6,792- 7,106)
Inpatient
73
243
104***
91***
77
103***
89***
208
115***
103***
OOP Costs
(8)
(63)
(93 - 115)
(80- 103)
(17)
(92 - 114)
(78- 100)
(28)
(104- 126)
(92- 114)
Outpatients
130
346
126***
141***
168
126***
141***
197
131*** (
145***
OOP Costs
(6)
(104)
(115- 137)
(132- 151)
(28)
(115- 137)
(131- 150)
(18)
120- 141)
(136- 154)
Prescription
624
1,096
549***
691***
1,115
550***
689***
1,014
561***
711***
OOP Costs
(9)
(70)
(543- 555)
(677- 706)
(90)
(544- 556)
(674- 703)
(27)
(555- 567)
(697- 725)
Other OOP
1,270
2,087
2,408***
1,248***
2,036
2,396***
1,242***
1,705
2,510***
1,269***
Costs
(45)
(196)
(2,347- 2,469)
(1,211- 1,286)
(373)
(2,335- 2,456)
(1,205- 1,279)
(132)
(2,449- 2,571)
(1,233- 1,305)
Note: Based on 38,089 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in fee-for-service Part A and Part B during the calendar
year and alive during the calendar year. Incremental costs were measured using counterfactual recycled predictions performed using estimates obtained from a 2-part GLM model with log link
and gamma distribution. The variables in the adjusted models were selected based on Andersen’s healthcare behavioral model and include sex, age, race, marital status, poverty, education,
prescription coverage, fragmented care, # ADL, # chronic conditions, # unique medications, overweight, smoking habit, and residency region.
COPD: Chronic Obstructive Pulmonary Disease; CRN: Cost-related Medication Non-Adherence; Ref: reference group; Sig: significance***p< .001; **.001 ≤ p < .01; *.01 ≤ p <.05
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Appendix 7.5
Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from
Separate Logistic Regressions on High Out-of-Pocket Burden
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
Unadjusted Model
Fully Adjusted Model
Asthma COPD Status
Asthma COPD Overlap
Asthma Only
COPD only
No asthma No COPD (ref)
Sex
Female
Male (ref)
Age in Years
Race/Ethnicity
White (ref)
Black
Latino
Other Races
Marital Status
Married
Not married (ref)
Education
Less than high school (ref)
High school
Above high school
Poverty Status
Less than 200% FPL
At least 200% FPL (ref)
Prescription Coverage
Yes
No (ref)
% Fragmented Care
# Other Chronic Conditions
# ADL
# Unique Medications
Overweight
Yes
No (ref)
Smoking habit
Current and Past
Never (ref)
Residency Region
Northeast
South
Midwest
West (ref)

UOR

95% CI

3.51
1.99
2.40

[ 2.96 , 4.16]
[ 1.68 , 2.36]
[ 2.20 , 2.61]
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Sig

AOR

95% CI

Sig

1.31
1.19
1.28

[ 1.07 , 1.61]
[ 0.99 , 1.42]
[ 1.16 , 1.42]

**
***

1.14

[ 1.05 , 1.23]

**

1.02

[ 1.01 , 1.02]

0.82
0.68
0.60

[ 0.72 , 0.94]
[ 0.56 , 0.83]
[ 0.50 , 0.72]

**
***
***

0.69

[ 0.64 , 0.74]

***

0.77
0.93

[ 0.68 , 0.86]
[ 0.84 , 1.03]

***

3.71

[ 3.44 , 4.00]

***

0.56

[ 0.52 , 0.60]

***

1.01
1.05
1.12
1.09

[ 1.01 ,
[ 1.02 ,
[ 1.09 ,
[ 1.08 ,

***
***
***
***

1.01

[ 0.94 , 1.10]

1.14

[ 0.93 , 1.34]

0.95
0.79
0.90

[ 0.81 , 1.11]
[ 0.71 , 0.87]
[ 0.80 , 1.01]

1.01]
1.09]
1.15]
1.10]

***

Appendix 7.6
Post-Regression Decomposition Analyses
Older (age > 65 years) Medicare Beneficiaries
Medicare Current Beneficiary Survey, 2006-2013
Average Log Total Healthcare Expenditures of asthma COPD overlap
Average Log Total Expenditures of asthma only group
Difference in Log Total Healthcare Expenditures
Total “explained” percentage
% Contribution to the “Explained” Portion
Predisposing characteristics (sex, age, race)
Enabling factors 1 (marital status, poverty, education, prescription coverage)
Enabling factor 2 (fragmented care)
Need Factors 1 (# ADL, # chronic conditions)
Need Factors 2 (# unique medications)
Personal healthcare practice (obesity, smoking)
External factors (residency region)
Average Log Total Healthcare Expenditures of asthma COPD overlap
Average Log Total Expenditures of COPD only group
Difference in Log Total Healthcare Expenditures
Total “explained” percentage
% Contribution to the “Explained” Portion
Predisposing characteristics (sex, age, race)
Enabling factors 1 (marital status, poverty, education, prescription coverage)
Enabling factor 2 (fragmented care)
Need Factors 1 (# ADL, # chronic conditions)
Need Factors 2 (# unique medications)
Personal healthcare practice (obesity, smoking)
External factors (residency region)

23.3893
20.1912
11.1627
76.42
3.70 %
-3.75%
11.48%*
42.05%
76.73%*
-21.12%
-9.08%
20.8304
20.0288
0.080157
45.12%
-109.10%
32.61%
29.12%
28.19%
61.51%***
56.63%
1.04%

Notes: Based on 38,089 elderly Medicare beneficiaries who were observed between years 2006 and 2013. The percent differences
of domains of Andersen’s healthcare behavior model are illustrated in the model.
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Appendix 7.7
Attrition Table of Individuals Included in the Analysis Based on Inclusion and Exclusion Criteria

Number of individuals available in MCBS 2006-2013
131,007

Number of individuls at least 65 yeas old
74,689

Number of individuals with at least one full year enrollment
70,470

Number of individuls with community-dwelling status
68,512

Number of individuals who were alive during calendar year
63,923

Number of individuls who are enrolled in fee-for-service program
61,870

Number of individuals whose information was available in both "access to care" and "cost and use" files
37,817

Number of individuls wihout any missing values for cost-related medication non-adherence

37,571
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Appendix 7.8
Characteristics of Elderly Community-Dwelling Fee-for-Service Medicare Beneficiaries
N
Wt. %
ALL
37,571
100.0
Sex
Female
21,186
56.2
Male
16,385
43.8
Age in Years
65-74
14,893
47.4
75-84
15,447
37.5
85 and above
7,231
15.1
Race/Ethnicity
White
31,130
82.7
Black
2,563
6.6
Latino
2,112
5.7
Other race
1,688
4.8
Marital Status
Married
19,507
54.2
Not married
18,050
45.7
Education
Less than high school
9,145
22.2
High school
13,573
35.5
Above high school
14,711
41.9
Poverty Status
Less than 200% FPL
18,120
45.6
At least 200% FPL
19,451
54.4
Prescription Coverage
Yes
23,380
61.6
No
14,191
38.4
OOP High Burden-Prescription Costs
Yes
1,805
4.5
No
35,766
95.5
OOP High Burden – Medical Costs
Yes
4,885
12.3
No
32,686
87.7
Number of Unique Medications
0
1,665
5.0
1-4
9,142
25.3
5-7
8,906
23.5
8-11
8,810
22.9
12 and more
9,048
23.3
Number of Other Chronic Conditions
0-1
7,687
22.2
2-3
20,037
53.1
4-6
9,842
24.7
Calendar Year
2006
5,694
13.2
2007
5,321
12.3
2008
4,904
11.7
2009
4,265
11.4
2010
4,001
11.4
2011
4,581
13.4
2012
4,546
13.2
2013
4,259
13.3
Note: Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries
continuously enrolled in fee-for-service Part A and Part B during the calendar year, alive during the calendar year,
had information in both cost and use and access to care files and did not have missing information on any costrelated medication nonadherence measures.
FPL: federal poverty level; N: unweighted number; Wt: weighted.
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Appendix 7.9
Attrition Table of Individuals Included in the Analysis Based on Inclusion and Exclusion Criteria
Number of individuals who used ICs
or ICS/LABA 2007-2017
• 250,508
Number of individuals who initiated
maintenance therapy 2008-2017
• 204,997
Number of individuals with age at
least 65 years old
• 56,650
Number of individuls with Medicare
plans
• 48,163
Number of individuals with at least
one year baseline and one year
follow-up continouse enrollment
• 15,956
Number of individuls with asthma
COPD overlap diagnosis in baseline
• 2,241

Number of individuals who did not
use LABA or LAMA during
baseline
• 1,562
Number of individuls wihout any
missing values for region
• 1,554

Number of individuals on
ICS/LABA
• 1,137

Number of individuals on ICS
• 417
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Appendix 7.10
Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from
Generalized Estimating Equation (GEE) on Adherence
among older adults with ACO Who Newly Initiated Maintenance Therapy
Optum Clinformatics 10% Sample, 2008-2016

ICS/LABA

Time

Time SQ

Diabetes

# SABA

0

1

2

Adjusted Odds Ratios
Note: Based on 1,556 Medicare beneficiaries (age > 65 years old) with ACO diagnosis and newly IMT (either
ICS or ICS/LABA) who were continuously enrolled 24 months during the observation period. In the graph, we
only illustrated the variables with significant association with adherence. The GEE model was adjusted by time,
square time and all factors based on Andersen’s model.
Abbreviations: ICS/LABA: Fixed dose combination of inhaled corticosteroid-and-long-acting beta agonist;
OOP: Out of Pocket; ref: reference group; SABA: Short-Acting Beta Agonist; SQ: Square; #: Number
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Appendix 7.11
Characteristics of Older Adults with Asthma-COPD Overlap
by Initial Maintenance Therapy Options
before Using Inverse Probability Treatment Weighting
Optum Clinformatics 10% Sample, 2007-2017
Total
ICS/LABA
ICS
N/
Percent/
N/
Percent/
N/
Percent/
Mean
SD
Mean
SD
Mean
SD
1554
100.0
1137
73.2
417
26.8

ALL
Sex

Sig

+
Female
Male

Age
Insurance Plan
HMO
Non- HMO
OOP Prescription Costs (per $100)
Depression
Yes
No
Anxiety
Yes
No
Diabetes
Yes
No
Hypertension
Yes
No
Heart Diseases
Yes
No
# Other Chronic Conditions
0
1-2
3-4
5 and more
# SABA
0
1-3
4-6
>7
Polypharmacy
Yes
No
Obesity Diagnosis
Yes
No
Tobacco Use Diagnosis
Yes
No
Region
Northeast
Midwest
South
West

1035
519
75.2

66.6
33.4
6.1

743
394

65.3
34.7

292
125

70.0
30.0

75.7

6.3

75.0

6.1

1009
545
5.4

64.9
35.1
7.4

709
428
5.3

62.4
37.6
7.0

300
117
5.9

71.9
28.1
9.1

201
1353

12.9
87.1

142
995

12.5
87.5

59
358

14.1
85.9

163
1391

10.5
89.5

108
1029

9.5
90.5

55
362

13.2
86.8

569
985

36.6
63.4

410
727

36.1
63.9

159
258

38.1
61.9

1105
449

71.1
28.9

805
332

70.8
29.2

300
117

71.9
28.1

652
902

42.0
58.0

480
657

42.2
57.8

172
245

41.2
58.8

132
444
601
377

8.5
28.6
38.7
24.3

107
327
426
277

9.4
28.8
37.5
24.4

25
117
175
100

6.0
28.1
42.0
24.0

573
758
142
81

36.9
48.8
9.1
5.2

432
531
109
65

38.0
46.7
9.6
5.7

141
227
33
16

33.8
54.4
7.9
3.8

1097
457

70.6
29.4

794
343

69.8
30.2

303
114

72.7
27.3

260
1294

16.7
83.3

198
939

17.4
82.6

62
355

14.9
85.1

196
1358

12.6
87.4

153
984

13.5
86.5

43
374

10.3
89.7

172
273
605
504

11.1
17.6
38.9
32.4

123
201
477
336

10.8
17.7
42.0
29.6

49
72
128
168

11.8
17.3
30.7
40.3

***

*

*

+

***

Note: Based on 1,556 Medicare beneficiaries (age > 65 years old) with ACO diagnosis and newly IMT (either ICS or ICS/LABA) who were
continuously enrolled 24 months during the observation period.
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Abbreviations: ACO: Asthma COPD Overlap; HMO: Health Maintenance Organization; ICS: Inhaled Corticosteroid;
ICS/LABA: Fixed dose combination of inhaled corticosteroid-and-long-acting beta agonist; IMT: Initial Maintenance Therapy; N:
Number; OOP: Out of Pocket; SABA: Short-Acting Beta Agonist; SD: Standard deviation; Sig: Significance; #: Number
***p<.001,**.001<p<.01,*.01<p<.005,+ .05< p<.1

101

